<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Ranitidine</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Ranitidine">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Ranitidine</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Ranitidine</b>, sold under the trade name <b>Zantac</b> among others, is a medication that decreases stomach acid production.<span class="mw-ref" id="cite_ref-AHFS2015_3-1"><a href="#cite_note-AHFS2015-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It is commonly used in treatment of peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome.<span class="mw-ref" id="cite_ref-AHFS2015_3-2"><a href="#cite_note-AHFS2015-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span>  There is also tentative evidence of benefit for hives.<span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span>  It can be taken by mouth, by injection into a muscle, or into a vein.<span class="mw-ref" id="cite_ref-AHFS2015_3-3"><a href="#cite_note-AHFS2015-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>



<p>
</p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Ranitidine</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Ranitidine.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Ranitidine.svg.png" data-file-width="512" data-file-height="437" data-file-type="drawing" height="213" width="250"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Ranitidine-A-3D-balls.png" tppabs="https://ptable.com/wiki/compounds/I/m/Ranitidine-A-3D-balls.png" data-file-width="1100" data-file-height="649" data-file-type="bitmap" height="148" width="250"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pronunciation</th><td><span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>r</span><span>ə</span><span>ˈ</span><span>n</span><span>ɪ</span><span>t</span><span>ɪ</span><span>d</span><span>iː</span><span>n</span></span>/</span></span><span> </span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Zantac<span class="mw-ref" id="cite_ref-Patient.info_1-0"><a href="#cite_note-Patient.info-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> <small>(original)</small>, and others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>Dimethyl [(5-{[(2-{[1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine, ranitidine hydrochloride (JAN <small><abbr>JP</abbr></small>)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/ranitidine-hydrochloride.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/ranitidine-hydrochloride.html'" tppabs="https://www.drugs.com/monograph/ranitidine-hydrochloride.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a601106.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a601106.html'" tppabs="https://medlineplus.gov/druginfo/meds/a601106.html" class="external text external">a601106</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ranitidine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ranitidine'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ranitidine" class="external text external">Ranitidine</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Ranitidine&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Ranitidine&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Ranitidine&SearchType=BasicSearch" class="external text external">Ranitidine</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>B1<span> </span><span class="mw-ref" id="cite_ref-RanitidinePregnancy_2-0"><a href="#cite_note-RanitidinePregnancy-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>B (No risk in non-human studies)<span> </span><span class="mw-ref" id="cite_ref-RanitidinePregnancy_2-1"><a href="#cite_note-RanitidinePregnancy-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth, intravenous (IV)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>Histamine H<sub>2</sub> receptor antagonist, aka H2 blocker<span class="mw-ref" id="cite_ref-Patient.info_1-1"><a href="#cite_note-Patient.info-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>A02BA02<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=A02BA02  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=A02BA02'" tppabs="https://www.whocc.no/atc_ddd_index/?code=A02BA02" class="external text external">WHO</a></span>)<span> </span><br>A02BA07<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=A02BA07  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=A02BA07'" tppabs="https://www.whocc.no/atc_ddd_index/?code=A02BA07" class="external text external">WHO</a></span>) (ranitidine bismuth citrate)</li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span>/<span>&nbsp;</span>S2 (Pharmacy Medicine)</li>
<li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span>/<span>&nbsp;</span>GSL (General sales list)</li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span>/<span>&nbsp;</span>OTC</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>50% (by mouth)<span class="mw-ref" id="cite_ref-AHFS2015_3-0"><a href="#cite_note-AHFS2015-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>15%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Liver: FMOs, including FMO3; other enzymes</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Onset of action</th><td>55–65<span>&nbsp;</span>minutes (150<span>&nbsp;</span>mg dose)<span class="mw-ref" id="cite_ref-pmid12144582_4-0"><a href="#cite_note-pmid12144582-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><br>55–115<span>&nbsp;</span>minutes (75<span>&nbsp;</span>mg dose)<span class="mw-ref" id="cite_ref-pmid12144582_4-1"><a href="#cite_note-pmid12144582-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>2–3 hours</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>30–70% kidney</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;"><i>N</i>-(2-[(5-[(Dimethylamino)methyl]furan-2-yl)methylthio]ethyl)-<i>N'</i>-methyl-2-nitroethene-1,1-diamine</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=66357-35-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=66357-35-5'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=66357-35-5" class="external text external">66357-35-5</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/3001055  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/3001055'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/3001055" class="external text external">3001055</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1234  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1234'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1234" class="external text external">1234</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00863  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00863'" tppabs="https://www.drugbank.ca/drugs/DB00863" class="external text external">DB00863</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.4863.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.4863.html'" tppabs="http://www.chemspider.com/Chemical-Structure.4863.html" class="external text external">4863</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=884KT10YB7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=884KT10YB7'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=884KT10YB7" class="external text external">884KT10YB7</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D00422  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D00422'" tppabs="https://www.kegg.jp/entry/D00422" class="external text external">D00422</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8776  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8776'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8776" class="external text external">CHEBI:8776</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1790041  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1790041'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1790041" class="external text external">ChEMBL1790041</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID8045191  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID8045191'" tppabs="https://comptox.epa.gov/dashboard/DTXSID8045191" class="external text external">DTXSID8045191</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.060.283  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.060.283'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.060.283" class="external text external">100.060.283</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>13</sub><span>H</span><sub>22</sub><span>N</span><sub>4</sub><span>O</span><sub>3</sub><span>S</span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">314.40</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=%5BO-%5D%5BN%2B%5D%28+%3D+O%29C+%3D+C%28NC%29NCCSCc1ccc%28o1%29CN%28C%29C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=%5BO-%5D%5BN%2B%5D%28+%3D+O%29C+%3D+C%28NC%29NCCSCc1ccc%28o1%29CN%28C%29C'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=%5BO-%5D%5BN%2B%5D%28+%3D+O%29C+%3D+C%28NC%29NCCSCc1ccc%28o1%29CN%28C%29C" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">[O-][N+]( = O)C = C(NC)NCCSCc1ccc(o1)CN(C)C</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:VMXUWOKSQNHOCA-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458460406&page2=Ranitidine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458460406&page2=Ranitidine'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458460406&page2=Ranitidine" class="external text external">(verify)</a></span></span></td></tr></tbody></table>


<p>Common side effects include headaches, and pain or burning if given by injection.<span class="mw-ref" id="cite_ref-AHFS2015_3-4"><a href="#cite_note-AHFS2015-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span>  Serious side effects may include liver problems, a slow heart rate, pneumonia, and the potential of masking stomach cancer.<span class="mw-ref" id="cite_ref-AHFS2015_3-5"><a href="#cite_note-AHFS2015-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span>  It is also linked to an increased risk of <i>Clostridium difficile</i> colitis.<span class="mw-ref" id="cite_ref-6"><a href="#cite_note-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span>  It is generally safe in pregnancy.<span class="mw-ref" id="cite_ref-AHFS2015_3-6"><a href="#cite_note-AHFS2015-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Ranitidine is an H<sub>2</sub> histamine receptor antagonist that works by blocking <a href="Histamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine" title="Histamine">histamine</a>, and thus decreasing the amount of acid released by cells of the stomach.<span class="mw-ref" id="cite_ref-AHFS2015_3-7"><a href="#cite_note-AHFS2015-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>


<p>Ranitidine was discovered in England, UK in 1976, and came into commercial use in 1981.<span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> It is on the World Health Organization's List of Essential Medicines.<span class="mw-ref" id="cite_ref-WHO21st_8-0"><a href="#cite_note-WHO21st-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> It is available as a generic medication.<span class="mw-ref" id="cite_ref-AHFS2015_3-8"><a href="#cite_note-AHFS2015-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> In 2017, it was the 48th most commonly prescribed medication in the United States, with more than 16<span>&nbsp;</span>million prescriptions.<span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>


<p>In September 2019, the carcinogen <a href="N-Nitrosodimethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/N-Nitrosodimethylamine" title="N-Nitrosodimethylamine"><i>N</i>-nitrosodimethylamine</a> (NDMA) was discovered in ranitidine products from a number of manufacturers, resulting in recalls.<span class="mw-ref" id="cite_ref-HealthCanada_11-0"><a href="#cite_note-HealthCanada-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-FDA2019NDMA_12-0"><a href="#cite_note-FDA2019NDMA-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-EMA1_13-0"><a href="#cite_note-EMA1-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-FDA_NDMA_ranitidine_14-0"><a href="#cite_note-FDA_NDMA_ranitidine-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> In April 2020, it was withdrawn from the United States market and suspended in the European Union and in Australia due to these concerns.<span class="mw-ref" id="cite_ref-FDA_Q&amp;A_15-0"><a href="#cite_note-FDA_Q&amp;A-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-FDA_removal_PR_16-0"><a href="#cite_note-FDA_removal_PR-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-EU_suspension_PR_17-0"><a href="#cite_note-EU_suspension_PR-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span><span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>
<style data-mw-deduplicate="TemplateStyles:r886046785">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><meta property="mw:PageProp/toc"></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<ul><li>Relief of heartburn<span class="mw-ref" id="cite_ref-Patient.info_1-2"><a href="#cite_note-Patient.info-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li>Short-term, and maintenance therapy of gastric and duodenal ulcers<span class="mw-ref" id="cite_ref-Patient.info_1-3"><a href="#cite_note-Patient.info-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li>Ranitidine can also be given with nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce the risk of ulceration.<span class="mw-ref" id="cite_ref-Patient.info_1-4"><a href="#cite_note-Patient.info-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span>  Proton-pump inhibitors (PPIs) are more effective for the prevention of NSAID-induced ulcers.<span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></li>
<li>Pathologic gastro-intestinal (GI) hypersecretory conditions such as Zollinger–Ellison syndrome</li>
<li>Gastroesophageal reflux disease (GORD / GERD)</li>
<li>Erosive esophagitis</li>
<li>Part of a multi-drug regimen for <i>H. pylori</i> eradication to minimise the risk of duodenal ulcer recurrence</li>
<li>Recurrent post-operative ulcer</li>
<li>Upper GI bleeding</li>
<li>Prevention of acid-aspiration pneumonitis during surgery: ranitidine can be administered preoperatively to reduce the risk of aspiration pneumonia.  The drug increases gastric pH, but generally has no effect on gastric volume.  In a 2009, meta-analysis comparing the net benefit of proton pump inhibitors and ranitidine to reduce the risk of aspiration before anaesthesia, ranitidine was found to be more effective than proton pump inhibitors in reducing the volume of gastric secretions.<span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span>  Ranitidine may have an anti-emetic effect when administered preoperatively.</li>
<li>Prevention of stress-induced ulcers in critically ill patients<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></li>
<li>Used together with <a href="Diphenhydramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Diphenhydramine" title="Diphenhydramine">diphenhydramine</a> as secondary treatment for anaphylaxis; after first-line <a href="Epinephrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Epinephrine" title="Epinephrine" class="mw-redirect">epinephrine</a>.<span class="mw-ref" id="cite_ref-AAFP2003_22-0"><a href="#cite_note-AAFP2003-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-AAP2017_23-0"><a href="#cite_note-AAP2017-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span></li></ul>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Dosing">Dosing</h3></summary>
    
<p>For ulcer treatment, a night-time dose is especially important; as the increase in gastric / duodenal pH promotes healing overnight, when the stomach and duodenum are empty.  Conversely, for treating acid reflux, smaller and more frequent doses are more effective.</p>

<p>Ranitidine was originally administered long-term for acid reflux treatment, sometimes indefinitely.  However, for some, proton-pump inhibitors (PPIs) have taken over this role.  In addition, in children, a fairly rapid tachyphylaxis can develop within six weeks of initiation of treatment, further limiting its potential for long-term use.<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></p>

<p>People with Zollinger–Ellison syndrome have been given very high doses without any harm.<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindication">Contraindication</h2></summary>
    
<p>Ranitidine is contraindicated for people known to have excessive sensitivity to the drug.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    
<p>The following adverse effects for ranitidine have been reported as events in clinical trials:</p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Central_nervous_system">Central nervous system</h3></summary>
    
<p>Rare reports have been made of ranitidine causing malaise, dizziness, somnolence, insomnia, and vertigo.  In severely ill, elderly patients, cases of reversible mental confusion, agitation, depression, and hallucinations have been reported.<span class="mw-ref" id="cite_ref-ZANTAC_Drug_Insert_26-0"><a href="#cite_note-ZANTAC_Drug_Insert-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span>  Ranitidine causes fewer central nervous system (CNS) adverse reactions and drug interactions compared with <a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">cimetidine</a>.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Cardiovascular">Cardiovascular</h3></summary>
    
<p>Arrhythmias such as tachycardia, bradycardia, atrioventricular block, and premature ventricular beats have also been reported.<span class="mw-ref" id="cite_ref-ZANTAC_Drug_Insert_26-1"><a href="#cite_note-ZANTAC_Drug_Insert-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Gastrointestinal">Gastrointestinal</h3></summary>
    
<p>All drugs in the H<sub>2</sub> receptor blocker class of medicines have the potential to cause vitamin B<sub>12</sub> deficiency, secondary to a reduction in food-bound vitamin B<sub>12</sub> absorption.<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span>  Elderly patients taking H<sub>2</sub> receptor antagonists are more likely to require B<sub>12</sub> supplementation than those not taking such drugs.<span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span>  H<sub>2</sub> blockers may also reduce the absorption of drugs (azole antifungals, calcium carbonate) that require an acidic stomach.<span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span>  In addition, multiple studies suggest the use of H<sub>2</sub> receptor antagonists such as ranitidine may increase the risk of infectious diarrhoea, including traveller's diarrhoea and salmonellosis.<span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span><span class="mw-ref" id="cite_ref-pmid7906170_31-0"><a href="#cite_note-pmid7906170-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span><span class="mw-ref" id="cite_ref-pmid8601113_32-0"><a href="#cite_note-pmid8601113-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span><span class="mw-ref" id="cite_ref-33"><a href="#cite_note-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span><span class="mw-ref" id="cite_ref-34"><a href="#cite_note-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span>  A 2005 study found that by suppressing acid-mediated breakdown of proteins, ranitidine may lead to an elevated risk of developing food or drug allergies, due to undigested proteins then passing into the gastrointestinal tract, where sensitisation occurs.  Patients who take these agents develop higher levels of immunoglobulin E against food, whether they had prior antibodies or not.<span class="mw-ref" id="cite_ref-pmid15671152_35-0"><a href="#cite_note-pmid15671152-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span>  Even months after discontinuation, an elevated level of IgE in six percent of patients was still found in the study.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Liver">Liver</h3></summary>
    
<p>Cholestatic hepatitis, liver failure, hepatitis, and jaundice have been noted, and require immediate discontinuation of the drug.<span class="mw-ref" id="cite_ref-ZANTAC_Drug_Insert_26-2"><a href="#cite_note-ZANTAC_Drug_Insert-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span>  Blood tests can reveal an increase in liver enzymes or eosinophilia, although in rare instances, severe cases of hepatotoxicity may require a liver biopsy.<span class="mw-ref" id="cite_ref-36"><a href="#cite_note-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Lungs">Lungs</h3></summary>
    
<p>Ranitidine and other <a href="Histamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine" title="Histamine">histamine</a> H<sub>2</sub> receptor antagonists may increase the risk of pneumonia in hospitalised patients.<span class="mw-ref" id="cite_ref-37"><a href="#cite_note-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span>  They may also increase the risk of community-acquired pneumonia in adults and children.<span class="mw-ref" id="cite_ref-pmid16651285_38-0"><a href="#cite_note-pmid16651285-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Blood">Blood</h3></summary>
    
<p>Thrombocytopenia is a rare but known side effect.  Drug-induced thrombocytopenia usually takes weeks or months to appear, but may appear within 12<span>&nbsp;</span>hours of drug intake in a sensitised individual.  Typically, the platelet count falls to 80% of normal, and thrombocytopenia may be associated with neutropenia and anemia.<span class="mw-ref" id="cite_ref-pmid21455428_39-0"><a href="#cite_note-pmid21455428-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Skin">Skin</h3></summary>
    
<p>Rash, including rare cases of erythema multiforme, and rare cases of hair loss and vasculitis have been seen.<span class="mw-ref" id="cite_ref-ZANTAC_Drug_Insert_26-3"><a href="#cite_note-ZANTAC_Drug_Insert-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Precautions">Precautions</h2></summary>
    

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Disease-related_concerns">Disease-related concerns</h3></summary>
    
<p>Relief of symptoms due to the use of ranitidine does not exclude the presence of a gastric malignancy.  In addition, with kidney or liver impairment, ranitidine must be used with caution.  Ranitidine should be avoided in patients with porphyria, as it may precipitate an attack.<span class="mw-ref" id="cite_ref-40"><a href="#cite_note-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span><span class="mw-ref" id="cite_ref-41"><a href="#cite_note-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pregnancy">Pregnancy</h3></summary>
    

<p>Ranitidine is rated as pregnancy category B in the United States.<span class="mw-ref" id="cite_ref-RanitidinePregnancy_2-2"><a href="#cite_note-RanitidinePregnancy-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Lactation">Lactation</h3></summary>
    
<p>Ranitidine enters breast milk, with peak concentrations seen at 5.5<span>&nbsp;</span>hours after the dose in breast milk.  Caution should be exercised when prescribed to nursing women.<span class="mw-ref" id="cite_ref-42"><a href="#cite_note-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Children">Children</h3></summary>
    
<p>In children, the use of gastric acid inhibitors has been associated with an increased risk for development of acute gastroenteritis, and community-acquired pneumonia.<span class="mw-ref" id="cite_ref-43"><a href="#cite_note-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span>  A cohort analysis including over 11,000<span>&nbsp;</span>neonates reported an association of H<sub>2</sub> blocker use, and an increased incidence of necrotizing enterocolitis in very-low-birth-weight (VLBW) neonates.<span class="mw-ref" id="cite_ref-44"><a href="#cite_note-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span>  In addition, about a sixfold increase in mortality, necrotizing enterocolitis, and infection such as sepsis, pneumonia, urinary tract infection (UTI) was reported in patients receiving ranitidine in a cohort analysis of 274 VLBW neonates.<span class="mw-ref" id="cite_ref-45"><a href="#cite_note-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Drug_tests">Drug tests</h3></summary>
    
<p>Ranitidine may return a false positive result with some commercial urine drug screening kits for testing for drugs of abuse.<span class="mw-ref" id="cite_ref-46"><a href="#cite_note-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Cancer-causing_impurities">Cancer-causing impurities</h3></summary>
    
<p></p>
<p></p>
<div role="note" class="hatnote navigation-not-searchable">See also: <a href="Valsartan.htm#recalls" tppabs="https://ptable.com/wiki/compounds/A/Valsartan#recalls" title="Valsartan">Valsartan §<span>&nbsp;</span>recalls</a>, and Angiotensin II receptor blocker §<span>&nbsp;</span>recalls</div>
<p>In September 2019, the U.S. Food and Drug Administration (FDA) learned that some ranitidine medicines, including some products sold under the brand name Zantac, contained a <a href="Nitrosamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nitrosamine" title="Nitrosamine">nitrosamine</a> impurity called <a href="N-Nitrosodimethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/N-Nitrosodimethylamine" title="N-Nitrosodimethylamine"><i>N</i>-nitrosodimethylamine</a> (NDMA), classified as a probable human carcinogen, at low levels.<span class="mw-ref" id="cite_ref-FDA2019NDMA_12-1"><a href="#cite_note-FDA2019NDMA-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-FDA_Q&amp;A_15-1"><a href="#cite_note-FDA_Q&amp;A-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-47"><a href="#cite_note-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span> Health Canada (HC) announced that it was assessing NDMA in ranitidine<span class="mw-ref" id="cite_ref-HealthCanada_11-1"><a href="#cite_note-HealthCanada-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> and requested that manufacturers stop the distribution of ranitidine products in Canada until the NDMA levels in the products are found to be safe.<span class="mw-ref" id="cite_ref-Health_Canada_48-0"><a href="#cite_note-Health_Canada-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span>  Health Canada announced that ranitidine drugs were being recalled by Sandoz Canada, Apotex Inc., Pro Doc Limitée, Sanis Health Inc., and Sivem Pharmaceuticals ULC.<span class="mw-ref" id="cite_ref-Health_Canada_48-1"><a href="#cite_note-Health_Canada-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span>  The European Medicines Agency (EMA) started a European Union (EU) wide review of ranitidine medicines at the request of the European Commission.<span class="mw-ref" id="cite_ref-EMA1_13-1"><a href="#cite_note-EMA1-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-EMA2_49-0"><a href="#cite_note-EMA2-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span></p>

<p>In September 2019, Sandoz issued a "precautionary distribution stop" of all medicines containing ranitidine.<span class="mw-ref" id="cite_ref-SandozStop_50-0"><a href="#cite_note-SandozStop-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span><span class="mw-ref" id="cite_ref-51"><a href="#cite_note-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> followed a few days later by a recall of ranitidine hydrochloride capsules in the United States.<span class="mw-ref" id="cite_ref-52"><a href="#cite_note-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-53"><a href="#cite_note-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span><span class="mw-ref" id="cite_ref-54"><a href="#cite_note-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span>  The Italian Medicines Agency, AIFA, recalled all ranitidine that uses an active pharmaceutical ingredient (API) from Saraca Laboratories.<span class="mw-ref" id="cite_ref-55"><a href="#cite_note-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span><span class="mw-ref" id="cite_ref-56"><a href="#cite_note-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span><span class="mw-ref" id="cite_ref-57"><a href="#cite_note-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span>  The Federal Union of German Associations of Pharmacists (<i>Arzneimittelkommission der Deutschen Apotheker</i> (AMK)) published a list of recalled products.<span class="mw-ref" id="cite_ref-58"><a href="#cite_note-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span>  The Therapeutic Goods Administration (TGA) in Australia published a list of recalled products.<span class="mw-ref" id="cite_ref-59"><a href="#cite_note-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span></p>

<p>In September 2019, Apotex recalled all over-the-counter (OTC) ranitidine tablets sold in the United States at Walmart, Rite Aid, and Walgreens.<span class="mw-ref" id="cite_ref-60"><a href="#cite_note-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span><span class="mw-ref" id="cite_ref-61"><a href="#cite_note-61" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span>  Subsequently, Walmart, Rite Aid, Walgreens, and CVS removed Zantac and some generics from their shelves.<span class="mw-ref" id="cite_ref-62"><a href="#cite_note-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span><span class="mw-ref" id="cite_ref-63"><a href="#cite_note-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span><span class="mw-ref" id="cite_ref-64"><a href="#cite_note-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span><span class="mw-ref" id="cite_ref-65"><a href="#cite_note-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span><span class="mw-ref" id="cite_ref-66"><a href="#cite_note-66" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span></p>

<p>In October 2019, the U.S. Food and Drug Administration (FDA) observed that a third-party laboratory was using higher temperatures in its tests to look for nitrosamine impurities.  The NDMA was generated by the added heat, but the higher temperatures were recommended for using a gas chromatography–mass spectrometry (GC/MS) method to test for NDMA in <a href="Valsartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Valsartan" title="Valsartan">valsartan</a> and angiotensin II receptor blockers (ARBs).<span class="mw-ref" id="cite_ref-67"><a href="#cite_note-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span>  The FDA stated that it recommends using a liquid chromatography-high resolution mass spectrometry (LC-HRMS) testing protocol to test samples of ranitidine.<span class="mw-ref" id="cite_ref-68"><a href="#cite_note-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span>  Its LC-HRMS testing method does not use elevated temperatures, and has shown the presence of much lower levels of NDMA in ranitidine medicines than reported by the third-party laboratory.  International regulators using similar LC-MS testing methods have also shown the presence of low levels of NDMA in ranitidine samples.<span class="mw-ref" id="cite_ref-FDA_NDMA_ranitidine_14-1"><a href="#cite_note-FDA_NDMA_ranitidine-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span>  The FDA provided additional guidance about using another liquid chromatography-mass spectrometry (LC-MS) method based on a triple-quadrupole MS platform.<span class="mw-ref" id="cite_ref-FDA_NDMA_ranitidine_14-2"><a href="#cite_note-FDA_NDMA_ranitidine-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-69"><a href="#cite_note-69" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span></p>

<p>On 8 October 2019, the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom issued a Drug Alert for ranitidine; "to proactively communicate the recall to hospitals, pharmacies, dispensing practices, retailers and wholesalers in the UK".<span class="mw-ref" id="cite_ref-GSK-UK_70-0"><a href="#cite_note-GSK-UK-70" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span>  This included all Zantac branded preparations,<span class="mw-ref" id="cite_ref-71"><a href="#cite_note-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span><span class="mw-ref" id="cite_ref-72"><a href="#cite_note-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span> along with all generic preparations of ranitidine from Teva UK Limited,<span class="mw-ref" id="cite_ref-73"><a href="#cite_note-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span><span class="mw-ref" id="cite_ref-74"><a href="#cite_note-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span> Rosemont Pharmaceuticals Limited,<span class="mw-ref" id="cite_ref-75"><a href="#cite_note-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span> Omega Pharma Limited and Galpharm International Limited,<span class="mw-ref" id="cite_ref-76"><a href="#cite_note-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span> Perrigo Company plc,<span class="mw-ref" id="cite_ref-77"><a href="#cite_note-77" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span> Creo Pharma Limited and Tillomed Laboratories Limited,<span class="mw-ref" id="cite_ref-78"><a href="#cite_note-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span><span class="mw-ref" id="cite_ref-79"><a href="#cite_note-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span> OTC Concepts Ltd, Relonchem Ltd, Noumed Life Sciences Ltd, and Medreich Plc.,<span class="mw-ref" id="cite_ref-80"><a href="#cite_note-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span><span class="mw-ref" id="cite_ref-81"><a href="#cite_note-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span> Accord Healthcare,<span class="mw-ref" id="cite_ref-82"><a href="#cite_note-82" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></span> Medley Pharma Limited,<span class="mw-ref" id="cite_ref-83"><a href="#cite_note-83" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></span> and Medreich Plc.<span class="mw-ref" id="cite_ref-84"><a href="#cite_note-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span></p>

<p>On the 15 October 2019, the Department of Health and Social Care (DHSC) of the United Kingdom issued a Supply Distribution Alert (SDA/2019/005) for all oral formulations of ranitidine.<span class="mw-ref" id="cite_ref-85"><a href="#cite_note-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span></p>

<p>In October 2019, Sanofi recalled all over-the-counter Zantac in the United States and Canada,<span class="mw-ref" id="cite_ref-86"><a href="#cite_note-86" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span><span class="mw-ref" id="cite_ref-87"><a href="#cite_note-87" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span><span class="mw-ref" id="cite_ref-FDA_NDMA_ranitidine_14-3"><a href="#cite_note-FDA_NDMA_ranitidine-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span>  Perrigo issued a worldwide recall of ranitidine,<span class="mw-ref" id="cite_ref-88"><a href="#cite_note-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-FDA_NDMA_ranitidine_14-4"><a href="#cite_note-FDA_NDMA_ranitidine-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span>  Dr. Reddy's issued a recall of all ranitidine products in the United States,<span class="mw-ref" id="cite_ref-89"><a href="#cite_note-89" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span><span class="mw-ref" id="cite_ref-FDA_NDMA_ranitidine_14-5"><a href="#cite_note-FDA_NDMA_ranitidine-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> and
Novitium Pharma recalled all ranitidine hydrochloride capsules in the United States.<span class="mw-ref" id="cite_ref-90"><a href="#cite_note-90" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span><span class="mw-ref" id="cite_ref-FDA_NDMA_ranitidine_14-6"><a href="#cite_note-FDA_NDMA_ranitidine-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p>

<p>In November 2019, the FDA stated that their tests have found levels of NDMA in ranitidine and nizatidine that are similar to the levels you would expect to be exposed to if you ate common foods like grilled or smoked meats.<span class="mw-ref" id="cite_ref-FDA_Statement_91-0"><a href="#cite_note-FDA_Statement-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span><span class="mw-ref" id="cite_ref-FDA_Lab_tests_92-0"><a href="#cite_note-FDA_Lab_tests-92" style="counter-reset: mw-Ref 92;"><span class="mw-reflink-text">[92]</span></a></span>  They also stated that their simulated gastric fluid (SGF) model tests and their simulated intestinal fluid (SIF) model tests indicate that NDMA is not formed when exposed to acid in the stomach with a normal diet.<span class="mw-ref" id="cite_ref-FDA_Statement_91-1"><a href="#cite_note-FDA_Statement-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span><span class="mw-ref" id="cite_ref-FDA_Lab_tests_92-1"><a href="#cite_note-FDA_Lab_tests-92" style="counter-reset: mw-Ref 92;"><span class="mw-reflink-text">[92]</span></a></span>  The FDA advised companies to recall their ranitidine if testing shows levels of NDMA above the acceptable daily intake (96 nanograms per day or 0.32 parts per million for ranitidine).<span class="mw-ref" id="cite_ref-FDA_NDMA_ranitidine_14-7"><a href="#cite_note-FDA_NDMA_ranitidine-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span>  At the same time, they indicated that some levels of NDMA found in medicines still exceed what the FDA considers acceptable for these medicines.<span class="mw-ref" id="cite_ref-FDA_Statement_91-2"><a href="#cite_note-FDA_Statement-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span><span class="mw-ref" id="cite_ref-FDA_Lab_tests_92-2"><a href="#cite_note-FDA_Lab_tests-92" style="counter-reset: mw-Ref 92;"><span class="mw-reflink-text">[92]</span></a></span></p>

<p>In November 2019, Aurobindo Pharma, Amneal Pharmaceuticals, American Health Packaging, Golden State Medical Supply, and Precision Dose recalled some lots of ranitidine tablets, capsules, and syrup.<span class="mw-ref" id="cite_ref-93"><a href="#cite_note-93" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></span><span class="mw-ref" id="cite_ref-94"><a href="#cite_note-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span><span class="mw-ref" id="cite_ref-95"><a href="#cite_note-95" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span><span class="mw-ref" id="cite_ref-96"><a href="#cite_note-96" style="counter-reset: mw-Ref 96;"><span class="mw-reflink-text">[96]</span></a></span><span class="mw-ref" id="cite_ref-97"><a href="#cite_note-97" style="counter-reset: mw-Ref 97;"><span class="mw-reflink-text">[97]</span></a></span></p>

<p>In December 2019, the FDA asked manufacturers of ranitidine and nizatidine products to expand their testing for NDMA to include all lots of the medication before making them available to consumers.<span class="mw-ref" id="cite_ref-98"><a href="#cite_note-98" style="counter-reset: mw-Ref 98;"><span class="mw-reflink-text">[98]</span></a></span>  In December 2019, Glenmark Pharmaceutical Inc., USA recalled some lots of ranitidine tablets.<span class="mw-ref" id="cite_ref-99"><a href="#cite_note-99" style="counter-reset: mw-Ref 99;"><span class="mw-reflink-text">[99]</span></a></span></p>

<p>In January 2020, Appco Pharma LLC and Northwind Pharmaceuticals recalled some lots of ranitidine tablets and capsules.<span class="mw-ref" id="cite_ref-100"><a href="#cite_note-100" style="counter-reset: mw-Ref 100;"><span class="mw-reflink-text">[100]</span></a></span><span class="mw-ref" id="cite_ref-101"><a href="#cite_note-101" style="counter-reset: mw-Ref 101;"><span class="mw-reflink-text">[101]</span></a></span></p>

<p>In February 2020, American Health Packaging recalled some lots of ranitidine tablets manufactured by Amneal Pharmaceuticals.<span class="mw-ref" id="cite_ref-FDA_PR_102-0"><a href="#cite_note-FDA_PR-102" style="counter-reset: mw-Ref 102;"><span class="mw-reflink-text">[102]</span></a></span></p>

<p>In April 2020, the FDA requested a manufacturer's market withdrawal of ranitidine.<span class="mw-ref" id="cite_ref-FDA_removal_PR_16-1"><a href="#cite_note-FDA_removal_PR-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-103"><a href="#cite_note-103" style="counter-reset: mw-Ref 103;"><span class="mw-reflink-text">[103]</span></a></span> This means ranitidine products will not be available for new or existing prescriptions or over-the-counter (OTC) use in the U.S.<span class="mw-ref" id="cite_ref-FDA_Q&amp;A_15-2"><a href="#cite_note-FDA_Q&amp;A-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-FDA_removal_PR_16-2"><a href="#cite_note-FDA_removal_PR-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> New FDA testing and evaluation prompted by information from third-party laboratories confirmed that NDMA levels increase in ranitidine even under normal storage conditions, and NDMA has been found to increase significantly in samples stored at higher temperatures, including temperatures the product may be exposed to during distribution and handling by consumers.<span class="mw-ref" id="cite_ref-FDA_removal_PR_16-3"><a href="#cite_note-FDA_removal_PR-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> The testing also showed that the older a ranitidine product is, or the longer the length of time since it was manufactured, the greater the level of NDMA.<span class="mw-ref" id="cite_ref-FDA_removal_PR_16-4"><a href="#cite_note-FDA_removal_PR-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> These conditions may raise the level of NDMA in the ranitidine product above the acceptable daily intake limit.<span class="mw-ref" id="cite_ref-FDA_removal_PR_16-5"><a href="#cite_note-FDA_removal_PR-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>

<p>In April 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the suspension of all ranitidine medicines in the EU due to the presence of low levels NDMA.<span class="mw-ref" id="cite_ref-104"><a href="#cite_note-104" style="counter-reset: mw-Ref 104;"><span class="mw-reflink-text">[104]</span></a></span><span class="mw-ref" id="cite_ref-CHMP_withdrawl_105-0"><a href="#cite_note-CHMP_withdrawl-105" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></span><span class="mw-ref" id="cite_ref-EU_suspension_PR_17-1"><a href="#cite_note-EU_suspension_PR-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span> There is some evidence that NDMA may form from the degradation of ranitidine itself with increasing levels seen over its shelf life.<span class="mw-ref" id="cite_ref-CHMP_withdrawl_105-1"><a href="#cite_note-CHMP_withdrawl-105" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></span> It is not clear whether NDMA can also be formed from ranitidine inside the body.<span class="mw-ref" id="cite_ref-CHMP_withdrawl_105-2"><a href="#cite_note-CHMP_withdrawl-105" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></span> Some studies suggest that it can while others do not.<span class="mw-ref" id="cite_ref-CHMP_withdrawl_105-3"><a href="#cite_note-CHMP_withdrawl-105" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></span> Given the uncertainties, the CHMP has recommended a precautionary suspension of these medicines in the EU.<span class="mw-ref" id="cite_ref-CHMP_withdrawl_105-4"><a href="#cite_note-CHMP_withdrawl-105" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></span></p>

<p>In June 2020, one of the companies that markets ranitidine in the European Union requested a re-examination of the CHMP's April 2020 opinion.<span class="mw-ref" id="cite_ref-CHMP_withdrawl_105-5"><a href="#cite_note-CHMP_withdrawl-105" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></span></p>

<p>In August 2020, the European Medicines Agency (EMA) provided guidance to marketing authorization holders on how to avoid the presence of nitrosamine impurities in human medicines and asked them to review all chemical and biological human medicines for the possible presence of nitrosamines and to test the products at risk.<span class="mw-ref" id="cite_ref-EMA_Nitrosamine_impurities_106-0"><a href="#cite_note-EMA_Nitrosamine_impurities-106" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    



    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Mechanism_of_action">Mechanism of action</h3></summary>
    
<p>Ranitidine is a competitive, reversible inhibitor of the action of histamine at the histamine H<sub>2</sub> receptors found in gastric parietal cells.  This results in decreased gastric acid secretion and gastric volume, and reduced hydrogen ion concentration.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    
<p>Absorption:  Oral:  50%</p>

<p>Protein binding:  15%</p>

<p>Metabolism:  <i>N</i>-oxide is the principal metabolite.</p>

<p>Half-life elimination:  With normal renal function, ranitidine taken orally has a half-life of 2.5–3.0 hours.  If taken intravenously, the half-life is generally 2.0–2.5 hours in a patient with normal <a href="Creatinine.htm" tppabs="https://ptable.com/wiki/compounds/A/Creatinine" title="Creatinine">creatinine</a> clearance.</p>

<p>Excretion:  The primary route of excretion is the urine.  In addition, about 30% of the orally administered dose is collected in the urine as non-absorbed drug in 24 hours.</p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Elderly">Elderly</h4></summary>
    
<p>In the elderly population, the plasma half-life of ranitidine is prolonged to 3–4 hours secondary to decreased kidney function causing decreased clearance.<span class="mw-ref" id="cite_ref-ZANTAC_Drug_Insert_26-4"><a href="#cite_note-ZANTAC_Drug_Insert-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Children_2">Children</h4></summary>
    
<p>In general, studies of pediatric patients (aged one month to 16 years) have shown no significant differences in pharmacokinetic parameter values in comparison to healthy adults, when correction is made for body weight.<span class="mw-ref" id="cite_ref-ZANTAC_Drug_Insert_26-5"><a href="#cite_note-ZANTAC_Drug_Insert-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Zantac.jpg" tppabs="https://ptable.com/wiki/compounds/I/m/Zantac.jpg" data-file-width="1323" data-file-height="1708" data-file-type="bitmap" height="284" width="220"><div class="thumbcaption" style="text-align: left">Zantac 300<span>&nbsp;</span>mg tablets from GlaxoSmithKline (GSK)</div></div></div>
<p>Ranitidine was first prepared in England as AH19065 by John Bradshaw in the summer of 1977 in the Ware research laboratories of Allen &amp; Hanburys, part of the larger Glaxo organisation.<span class="mw-ref" id="cite_ref-107"><a href="#cite_note-107" style="counter-reset: mw-Ref 107;"><span class="mw-reflink-text">[107]</span></a></span><span class="mw-ref" id="cite_ref-108"><a href="#cite_note-108" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span>  Its development was a response to the first in class histamine H<sub>2</sub> receptor antagonist, <a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">cimetidine</a>, developed by Sir James Black at Smith, Kline and French, and launched in the United Kingdom as <b>Tagamet</b> in November 1976.  Both companies would eventually become merged as GlaxoSmithKline (GSK), following a sequence of mergers and acquisitions, starting with the integration of Allen &amp; Hanbury's Ltd and Glaxo to form Glaxo Group Research in 1979, and ultimately with the merger of Glaxo Wellcome and SmithKline Beecham in 2000.  Ranitidine was the result of a rational drug-design process using what was by then a fairly refined model of the histamine H<sub>2</sub> receptor and quantitative structure-activity relationships (QSAR).</p>

<p>Glaxo refined the model further, by replacing the <a href="Imidazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Imidazole" title="Imidazole">imidazole</a> ring of cimetidine with a <a href="Furan.htm" tppabs="https://ptable.com/wiki/compounds/A/Furan" title="Furan">furan</a> ring with a <a href="Nitrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Nitrogen" title="Nitrogen">nitrogen</a>-containing substituent, and in doing so developed ranitidine.  Ranitidine was found to have a far-improved tolerability profile (i.e. fewer adverse drug reactions), longer-lasting action, and 10 times the activity of cimetidine.  Ranitidine has 10% of the affinity that cimetidine has to CYP450, so it causes fewer side effects, but other H<sub>2</sub> blockers <a href="Famotidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Famotidine" title="Famotidine">famotidine</a> and <a href="Nizatidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nizatidine" title="Nizatidine">nizatidine</a> have no CYP450 significant interactions.<span class="mw-ref" id="cite_ref-109"><a href="#cite_note-109" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span></p>

<p>Ranitidine was introduced in 1981, and was the world's biggest-selling prescription drug by 1987.  Subsequently, it was largely superseded by the more effective proton-pump inhibitor (PPI) class of drugs, with <a href="Omeprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Omeprazole" title="Omeprazole">omeprazole</a> becoming the biggest-selling drug for many years.  When omeprazole and ranitidine were compared in a study of 144 people with severe inflammation and erosions or ulcers of the oesophagus, 85% of those treated with omeprazole healed within eight weeks, compared with 50% of those given ranitidine.  In addition, the omeprazole group reported earlier relief of heartburn symptoms.<span class="mw-ref" id="cite_ref-110"><a href="#cite_note-110" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span><span class="mw-ref" id="cite_ref-111"><a href="#cite_note-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Preparations">Preparations</h2></summary>
    
<span>

</span>
<p>Preparations of ranitidine products include oral tablets (75<span>&nbsp;</span>mg, 150<span>&nbsp;</span>mg, and 300<span>&nbsp;</span>mg), effervescent tablets, and syrups,<span class="mw-ref" id="cite_ref-Patient.info_1-5"><a href="#cite_note-Patient.info-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> and injectable solutions;<span class="mw-ref" id="cite_ref-GSK-UK_70-1"><a href="#cite_note-GSK-UK-70" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span> with doses of specific ranitidine product preparations are available 'over the counter' (OTC) in various countries.  In the United Kingdom (UK), only the lowest strength 75<span>&nbsp;</span>mg tablet is available to purchase without a prescription.<span class="mw-ref" id="cite_ref-Patient.info_1-6"><a href="#cite_note-Patient.info-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span>  In Australia, packs containing seven or fourteen doses of the 150<span>&nbsp;</span>mg tablet are available in supermarkets, small packs of 150<span>&nbsp;</span>mg and 300<span>&nbsp;</span>mg tablets are schedule 2 pharmacy medicines.  Larger doses and pack sizes require a prescription.  In the United States, 75<span>&nbsp;</span> and 150<span>&nbsp;</span>mg tablets are available OTC.  Since 2017, Zantac is marketed in the U.S. by Sanofi.<span class="mw-ref" id="cite_ref-112"><a href="#cite_note-112" style="counter-reset: mw-Ref 112;"><span class="mw-reflink-text">[112]</span></a></span><span class="mw-ref" id="cite_ref-113"><a href="#cite_note-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Patient.info-1"> <span id="mw-reference-text-cite_note-Patient.info-1" class="mw-reference-text"><cite id="CITEREFMichael_Stewart,_BPharm,_MRPharmS2018" class="citation web cs1">Michael Stewart, <small>BPharm, MRPharmS</small> (12 April 2018). <a href="javascript:if(confirm('https://patient.info/medicine/ranitidine-to-reduce-stomach-acid-zantac  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://patient.info/medicine/ranitidine-to-reduce-stomach-acid-zantac'" tppabs="https://patient.info/medicine/ranitidine-to-reduce-stomach-acid-zantac" class="external text external">"Zantac – Ranitidine to reduce stomach acid"</a>. <i>Patient.info</i>. Leeds, England, United Kingdom:  Patient Platform Limited<span class="reference-accessdate">. Retrieved <span class="nowrap">31 March</span> 2020</span>. <q>Ranitidine reduces the amount of acid produced by your stomach. Any side-effects are usually mild and do not last long.</q></cite><span class="cs1-maint citation-comment">CS1 maint: multiple names: authors list (link)</span></span></li><li id="cite_note-RanitidinePregnancy-2"> <span id="mw-reference-text-cite_note-RanitidinePregnancy-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/ranitidine.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/ranitidine.html'" tppabs="https://www.drugs.com/pregnancy/ranitidine.html" class="external text external">"Ranitidine use during pregnancy"</a>. <i>Drugs.com</i>. 2 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">18 December</span> 2019</span>.</cite></span></li><li id="cite_note-AHFS2015-3"> <span id="mw-reference-text-cite_note-AHFS2015-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/ranitidine-hydrochloride.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/ranitidine-hydrochloride.html'" tppabs="https://www.drugs.com/monograph/ranitidine-hydrochloride.html" class="external text external">"Ranitidine hydrochloride monograph"</a>. The American Society of Health-System Pharmacists. <a href="javascript:if(confirm('https://web.archive.org/web/20170909005129/https://www.drugs.com/monograph/ranitidine-hydrochloride.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170909005129/https://www.drugs.com/monograph/ranitidine-hydrochloride.html'" tppabs="https://web.archive.org/web/20170909005129/https://www.drugs.com/monograph/ranitidine-hydrochloride.html" class="external text external">Archived</a> from the original on 9 September 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">1 December</span> 2015</span>.</cite></span></li><li id="cite_note-pmid12144582-4"> <span id="mw-reference-text-cite_note-pmid12144582-4" class="mw-reference-text"><cite id="CITEREFGardnerCiociolaRobinsonMcIsaac2002" class="citation journal cs1">Gardner JD, Ciociola AA, Robinson M,  et al. (July 2002). "Determination of the time of onset of action of ranitidine and famotidine on intra-gastric acidity". <i>Aliment. Pharmacol. Ther</i>. <b>16</b> (7): 1317–1326. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1365-2036.2002.01291.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1365-2036.2002.01291.x'" tppabs="https://doi.org/10.1046%2Fj.1365-2036.2002.01291.x" class="external text external">10.1046/j.1365-2036.2002.01291.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12144582  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12144582'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12144582" class="external text external">12144582</a>.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite id="CITEREFFedorowiczvan_ZuurenHu2012" class="citation journal cs1">Fedorowicz Z, van Zuuren EJ, Hu N (14 March 2012). "Histamine H2-receptor antagonists for urticaria". <i>Cochrane Database Syst Rev</i> (3). doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD008596.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD008596.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD008596.pub2" class="external text external">10.1002/14651858.CD008596.pub2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22419335  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22419335'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22419335" class="external text external">22419335</a>. CD008596.</cite></span></li><li id="cite_note-6"> <span id="mw-reference-text-cite_note-6" class="mw-reference-text"><cite id="CITEREFTleyjehAbdulhakAbdulhakRiaz2013" class="citation journal cs1">Tleyjeh IM, Abdulhak AB, Abdulhak AA,  et al. (2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587620  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587620'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587620" class="external text external">"The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis"</a>. <i>PLoS ONE</i>. <b>8</b> (3): e56498. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2013PLoSO...856498T  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2013PLoSO...856498T'" tppabs="https://ui.adsabs.harvard.edu/abs/2013PLoSO...856498T" class="external text external">2013PLoSO...856498T</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1371%2Fjournal.pone.0056498  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1371%2Fjournal.pone.0056498'" tppabs="https://doi.org/10.1371%2Fjournal.pone.0056498" class="external text external">10.1371/journal.pone.0056498</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587620  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587620'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587620" class="external text external">3587620</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23469173  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23469173'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23469173" class="external text external">23469173</a>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite id="CITEREFFischerGanellin2006" class="citation book cs1">Fischer J, Ganellin CR (2006). <a href="javascript:if(confirm('https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA444  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA444'" tppabs="https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA444" class="external text external"><i>Analogue-based Drug Discovery</i></a>. John Wiley &amp; Sons. p.<span>&nbsp;</span>444. ISBN<span>&nbsp;</span><bdi>9783527607495</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20161220084238/https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA444  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161220084238/https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA444'" tppabs="https://web.archive.org/web/20161220084238/https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA444" class="external text external">Archived</a> from the original on 20 December 2016.</cite></span></li><li id="cite_note-WHO21st-8"> <span id="mw-reference-text-cite_note-WHO21st-8" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a></span>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Top300Drugs.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Top300Drugs.aspx'" tppabs="https://clincalc.com/DrugStats/Top300Drugs.aspx" class="external text external">"The Top 300 of 2020"</a>. <i>ClinCalc</i><span class="reference-accessdate">. Retrieved <span class="nowrap">8 March</span> 2020</span>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Drugs/Ranitidine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Drugs/Ranitidine'" tppabs="https://clincalc.com/DrugStats/Drugs/Ranitidine" class="external text external">"Ranitidine - Drug Usage Statistics"</a>. <i>ClinCalc</i>. 23 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">7 April</span> 2020</span>.</cite></span></li><li id="cite_note-HealthCanada-11"> <span id="mw-reference-text-cite_note-HealthCanada-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/70989a-eng.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/70989a-eng.php'" tppabs="https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/70989a-eng.php" class="external text external">"Health Canada assessing NDMA in ranitidine"</a>. <i>Health Canada</i>. 13 September 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190926211206/https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/70989a-eng.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190926211206/https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/70989a-eng.php'" tppabs="https://web.archive.org/web/20190926211206/https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/70989a-eng.php" class="external text external">Archived</a> from the original on 26 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">26 September</span> 2019</span>.</cite></span></li><li id="cite_note-FDA2019NDMA-12"> <span id="mw-reference-text-cite_note-FDA2019NDMA-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine'" tppabs="https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine" class="external text external">"Statement alerting patients and health care professionals of NDMA found in samples of ranitidine"</a>. <i>U.S. Food and Drug Administration</i>. 13 September 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190926210751/https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190926210751/https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine'" tppabs="https://web.archive.org/web/20190926210751/https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine" class="external text external">Archived</a> from the original on 26 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">26 September</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-EMA1-13"> <span id="mw-reference-text-cite_note-EMA1-13" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/news/ema-provide-guidance-avoiding-nitrosamines-human-medicines  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/news/ema-provide-guidance-avoiding-nitrosamines-human-medicines'" tppabs="https://www.ema.europa.eu/en/news/ema-provide-guidance-avoiding-nitrosamines-human-medicines" class="external text external">"EMA to provide guidance on avoiding nitrosamines in human medicines"</a>. <i>European Medicines Agency (EMA)</i> (Press release). 13 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">19 September</span> 2019</span>.</cite></span></li><li id="cite_note-FDA_NDMA_ranitidine-14"> <span id="mw-reference-text-cite_note-FDA_NDMA_ranitidine-14" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine'" tppabs="https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine" class="external text external">"FDA updates and press announcements on NDMA in Zantac (ranitidine)"</a>. <i>U.S. Food and Drug Administration</i>. 28 October 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191029011848/https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191029011848/https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine'" tppabs="https://web.archive.org/web/20191029011848/https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine" class="external text external">Archived</a> from the original on 29 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">28 October</span> 2019</span>. <q>FDA observed the testing method used by a third-party laboratory uses higher temperatures.  The higher temperatures generated very high levels of NDMA from ranitidine products because of the test procedure.  FDA published the method for testing angiotensin II receptor blockers (ARBs) for nitrosamine impurities.  That method is not suitable for testing ranitidine because heating the sample generates NDMA.<br>FDA recommends using an LC-HRMS testing protocol to test samples of ranitidine.  FDA's LC-HRMS testing method does not use elevated temperatures and has shown the presence of much lower levels of NDMA in ranitidine medicines than reported by the third-party laboratory.  International regulators using similar LC-MS testing methods have also shown the presence of low levels of NDMA in ranitidine samples.</q></cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-FDA_Q&amp;A-15"> <span id="mw-reference-text-cite_note-FDA_Q&amp;A-15" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-ndma-impurities-ranitidine-commonly-known-zantac  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-ndma-impurities-ranitidine-commonly-known-zantac'" tppabs="https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-ndma-impurities-ranitidine-commonly-known-zantac" class="external text external">"Questions and Answers: NDMA impurities in ranitidine (commonly known as Zantac)"</a>. <i>U.S. Food and Drug Administration</i>. 11 October 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191024040431/https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-ndma-impurities-ranitidine-commonly-known-zantac  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191024040431/https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-ndma-impurities-ranitidine-commonly-known-zantac'" tppabs="https://web.archive.org/web/20191024040431/https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-ndma-impurities-ranitidine-commonly-known-zantac" class="external text external">Archived</a> from the original on 24 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">23 October</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-FDA_removal_PR-16"> <span id="mw-reference-text-cite_note-FDA_removal_PR-16" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market'" tppabs="https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market" class="external text external">"FDA Requests Removal of All Ranitidine Products (Zantac) from the Market"</a>. <i>U.S. Food and Drug Administration (FDA)</i> (Press release). 1 April 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">1 April</span> 2020</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-EU_suspension_PR-17"> <span id="mw-reference-text-cite_note-EU_suspension_PR-17" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/news/suspension-ranitidine-medicines-eu  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/news/suspension-ranitidine-medicines-eu'" tppabs="https://www.ema.europa.eu/en/news/suspension-ranitidine-medicines-eu" class="external text external">"Suspension of ranitidine medicines in the EU"</a>. <i>European Medicines Agency</i> (Press release). 30 April 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">2 June</span> 2020</span>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.tga.gov.au/node/882059  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.tga.gov.au/node/882059'" tppabs="https://www.tga.gov.au/node/882059" class="external text external">"Ranitidine"</a>. <i>Therapeutic Goods Administration (TGA)</i>. 2 April 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">19 July</span> 2020</span>.</cite></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://pharmasight.org/otc/reflux-remedies-ranitidine-zantac/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://pharmasight.org/otc/reflux-remedies-ranitidine-zantac/'" tppabs="http://pharmasight.org/otc/reflux-remedies-ranitidine-zantac/" class="external text external">"Reflux Remedies: ranitidine"</a>. <i>PharmaSight OTC Health</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20130112091347/http://pharmasight.org/otc/reflux-remedies-ranitidine-zantac/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130112091347/http://pharmasight.org/otc/reflux-remedies-ranitidine-zantac/'" tppabs="https://web.archive.org/web/20130112091347/http://pharmasight.org/otc/reflux-remedies-ranitidine-zantac/" class="external text external">Archived</a> from the original on 12 January 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">16 November</span> 2011</span>.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><cite id="CITEREFClarkLamGibsonCurrow2009" class="citation journal cs1">Clark K, Lam LT, Gibson S,  et al. (2009). "The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials". <i>Anaesthesia</i>. <b>64</b> (6): 652–657. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2044.2008.05861.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2044.2008.05861.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2044.2008.05861.x" class="external text external">10.1111/j.1365-2044.2008.05861.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19453319  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19453319'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19453319" class="external text external">19453319</a>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite id="CITEREFDellingerLevyRhodesAnnane2013" class="citation journal cs1">Dellinger RP, Levy MM, Rhodes A,  et al. (2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616" class="external text external">"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012"</a>. <i>Intensive Care Med</i>. <b>39</b> (2): 165–228. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs00134-012-2769-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs00134-012-2769-8'" tppabs="https://doi.org/10.1007%2Fs00134-012-2769-8" class="external text external">10.1007/s00134-012-2769-8</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616" class="external text external">2249616</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23361625  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23361625'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23361625" class="external text external">23361625</a>.</cite></span></li><li id="cite_note-AAFP2003-22"> <span id="mw-reference-text-cite_note-AAFP2003-22" class="mw-reference-text"><cite id="CITEREFTang2003" class="citation journal cs1">Tang AW (October 2003). <a href="javascript:if(confirm('https://www.aafp.org/afp/2003/1001/p1325.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.aafp.org/afp/2003/1001/p1325.html'" tppabs="https://www.aafp.org/afp/2003/1001/p1325.html" class="external text external">"A practical guide to anaphylaxis"</a>. <i>Am Fam Physician</i>. <b>68</b> (7): 1325–32. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14567487  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14567487'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14567487" class="external text external">14567487</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20170110092510/https://www.aafp.org/afp/2003/1001/p1325.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170110092510/https://www.aafp.org/afp/2003/1001/p1325.html'" tppabs="https://web.archive.org/web/20170110092510/https://www.aafp.org/afp/2003/1001/p1325.html" class="external text external">Archived</a> from the original on 10 January 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">3 February</span> 2017</span>.</cite></span></li><li id="cite_note-AAP2017-23"> <span id="mw-reference-text-cite_note-AAP2017-23" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.aapsus.org/userfiles/files/ajcm4.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.aapsus.org/userfiles/files/ajcm4.pdf'" tppabs="http://www.aapsus.org/userfiles/files/ajcm4.pdf" class="external text external">"Anaphylaxis: Diagnosis and Management in the Rural Emergency Department"</a> <span class="cs1-format">(PDF)</span>. American Journal of Clinical Medicine. <a href="javascript:if(confirm('https://web.archive.org/web/20160814133304/http://www.aapsus.org/userfiles/files/AJCM4.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160814133304/http://www.aapsus.org/userfiles/files/AJCM4.pdf'" tppabs="https://web.archive.org/web/20160814133304/http://www.aapsus.org/userfiles/files/AJCM4.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 14 August 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">3 February</span> 2017</span>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite id="CITEREFLightdaleGremseSection_on_Gastroenterology,_Hepatology,_and_Nutrition2013" class="citation journal cs1">Lightdale JR, Gremse DA, Section on Gastroenterology, Hepatology, and Nutrition (2013). <a href="javascript:if(confirm('https://doi.org/10.1542/peds.2013-0421  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1542/peds.2013-0421'" tppabs="https://doi.org/10.1542/peds.2013-0421" class="external text external">"Gastroesophageal reflux: management guidance for the pediatrician"</a>. <i>Pediatrics</i>. <b>131</b> (5): e1684–e1695. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1542%2Fpeds.2013-0421  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1542%2Fpeds.2013-0421'" tppabs="https://doi.org/10.1542%2Fpeds.2013-0421" class="external text external">10.1542/peds.2013-0421</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23629618  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23629618'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23629618" class="external text external">23629618</a>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613#doa'" tppabs="http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613#doa" class="external text external">"Ranitidine Drug Information"</a>. Lexicomp. <a href="javascript:if(confirm('https://web.archive.org/web/20140420014925/http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140420014925/http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613#doa'" tppabs="https://web.archive.org/web/20140420014925/http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613#doa" class="external text external">Archived</a> from the original on 20 April 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">20 April</span> 2014</span>.</cite></span></li><li id="cite_note-ZANTAC_Drug_Insert-26"> <span id="mw-reference-text-cite_note-ZANTAC_Drug_Insert-26" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018703s068,019675s035,020251s019lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018703s068,019675s035,020251s019lbl.pdf'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018703s068,019675s035,020251s019lbl.pdf" class="external text external">"Zantac drug insert"</a> <span class="cs1-format">(PDF)</span>. U.S. Food and Drug Administration (FDA). <a href="javascript:if(confirm('https://web.archive.org/web/20140420003039/https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018703s068,019675s035,020251s019lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140420003039/https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018703s068,019675s035,020251s019lbl.pdf'" tppabs="https://web.archive.org/web/20140420003039/https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018703s068,019675s035,020251s019lbl.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 20 April 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">19 April</span> 2014</span>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite id="CITEREFForceNahata1992" class="citation journal cs1">Force RW, Nahata MC (1992). "Effect of histamine H2-receptor antagonists on vitamin B12 absorption". <i>Ann Pharmacother</i>. <b>26</b> (10): 1283–1286. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F106002809202601018  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F106002809202601018'" tppabs="https://doi.org/10.1177%2F106002809202601018" class="external text external">10.1177/106002809202601018</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1358279  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1358279'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1358279" class="external text external">1358279</a>.</cite></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text"><cite id="CITEREFMitchellRockwood2001" class="citation journal cs1">Mitchell SL, Rockwood K (2001). "The association between antiulcer medication and initiation of cobalamin replacement in older persons". <i>J Clin Epidemiol</i>. <b>54</b> (5): 531–534. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0895-4356%2800%2900340-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0895-4356%2800%2900340-1'" tppabs="https://doi.org/10.1016%2FS0895-4356%2800%2900340-1" class="external text external">10.1016/S0895-4356(00)00340-1</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11337218  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11337218'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11337218" class="external text external">11337218</a>.</cite></span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://pharmasight.org/overthecounter/2011/11/15/reflux-remedies-ranitidine-zantac/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://pharmasight.org/overthecounter/2011/11/15/reflux-remedies-ranitidine-zantac/'" tppabs="http://pharmasight.org/overthecounter/2011/11/15/reflux-remedies-ranitidine-zantac/" class="external text external">"Reflux Remedies: ranitidine"</a>. <i>PharmaSight OTC Health</i>. PharmaSight.org. <a href="javascript:if(confirm('https://web.archive.org/web/20170821045645/http://pharmasight.org/overthecounter/2011/11/15/reflux-remedies-ranitidine-zantac/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170821045645/http://pharmasight.org/overthecounter/2011/11/15/reflux-remedies-ranitidine-zantac/'" tppabs="https://web.archive.org/web/20170821045645/http://pharmasight.org/overthecounter/2011/11/15/reflux-remedies-ranitidine-zantac/" class="external text external">Archived</a> from the original on 21 August 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">16 November</span> 2011</span>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite id="CITEREFCobelensLeentvarr-KuijpersKleijnenCoutinho1998" class="citation journal cs1">Cobelens FG, Leentvarr-Kuijpers A, Kleijnen J,  et al. (November 1998). "Incidence and risk factors of diarrhoea in Dutch travellers: Consequences for priorities in pre-travel health advice". <i>Trop Med Intern Health</i>. <b>3</b> (11): 896–903. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9855403  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9855403'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9855403" class="external text external">9855403</a>.</cite></span></li><li id="cite_note-pmid7906170-31"> <span id="mw-reference-text-cite_note-pmid7906170-31" class="mw-reference-text"><cite id="CITEREFNealBrijiSlackHawkey1994" class="citation journal cs1">Neal KR, Briji SO, Slack RC,  et al. (1994). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2542523  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2542523'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2542523" class="external text external">"Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection"</a>. <i>BMJ</i>. <b>308</b> (6922): 176. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.308.6922.176  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.308.6922.176'" tppabs="https://doi.org/10.1136%2Fbmj.308.6922.176" class="external text external">10.1136/bmj.308.6922.176</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2542523  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2542523'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2542523" class="external text external">2542523</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7906170  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7906170'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7906170" class="external text external">7906170</a>.</cite></span></li><li id="cite_note-pmid8601113-32"> <span id="mw-reference-text-cite_note-pmid8601113-32" class="mw-reference-text"><cite id="CITEREFNealScottSlackLogan1996" class="citation journal cs1">Neal KR, Scott HM, Slack RC,  et al. (1996). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2350063  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2350063'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2350063" class="external text external">"Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study"</a>. <i>BMJ</i>. <b>312</b> (7028): 414–415. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.312.7028.414  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.312.7028.414'" tppabs="https://doi.org/10.1136%2Fbmj.312.7028.414" class="external text external">10.1136/bmj.312.7028.414</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2350063  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2350063'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2350063" class="external text external">2350063</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8601113  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8601113'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8601113" class="external text external">8601113</a>.</cite></span></li><li id="cite_note-33"> <span id="mw-reference-text-cite_note-33" class="mw-reference-text"><cite id="CITEREFWickramasingheBasu1984" class="citation journal cs1">Wickramasinghe LS, Basu SK (1984). <a href="javascript:if(confirm('https://doi.org/10.1136/bmj.289.6454.1272  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136/bmj.289.6454.1272'" tppabs="https://doi.org/10.1136/bmj.289.6454.1272" class="external text external">"Salmonellosis during treatment with ranitidine"</a>. Unreviewed reports. <i>BMJ</i>. <b>289</b> (6454): 1272. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.289.6454.1272  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.289.6454.1272'" tppabs="https://doi.org/10.1136%2Fbmj.289.6454.1272" class="external text external">10.1136/bmj.289.6454.1272</a></span>.</cite></span></li><li id="cite_note-34"> <span id="mw-reference-text-cite_note-34" class="mw-reference-text"><cite id="CITEREFRuddellAxonFindlayBartholomew1980" class="citation journal cs1">Ruddell WS, Axon AT, Findlay JM,  et al. (1980). "Effect of cimetidine on gastric bacterial flora". <i>Lancet</i>. <b>i</b> (8170): 672–674. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0140-6736%2880%2992826-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0140-6736%2880%2992826-3'" tppabs="https://doi.org/10.1016%2Fs0140-6736%2880%2992826-3" class="external text external">10.1016/s0140-6736(80)92826-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6103090  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6103090'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6103090" class="external text external">6103090</a>.</cite></span></li><li id="cite_note-pmid15671152-35"> <span id="mw-reference-text-cite_note-pmid15671152-35" class="mw-reference-text"><cite id="CITEREFUntersmayrBakosSchöllKundi2005" class="citation journal cs1">Untersmayr E, Bakos N, Schöll I,  et al. (2005). "Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients". <i>FASEB J</i>. <b>19</b> (6): 656–658. doi:<a href="javascript:if(confirm('https://doi.org/10.1096%2Ffj.04-3170fje  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1096%2Ffj.04-3170fje'" tppabs="https://doi.org/10.1096%2Ffj.04-3170fje" class="external text external">10.1096/fj.04-3170fje</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15671152  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15671152'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15671152" class="external text external">15671152</a>.</cite></span></li><li id="cite_note-36"> <span id="mw-reference-text-cite_note-36" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://livertox.nlm.nih.gov/Ranitidine.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://livertox.nlm.nih.gov/Ranitidine.htm'" tppabs="http://livertox.nlm.nih.gov/Ranitidine.htm" class="external text external">"Ranitidine: Hepatotoxicity"</a>. <i>U.S. National Institutes of Health (NIH)</i>. 28 June 2016. <a href="javascript:if(confirm('https://web.archive.org/web/20160828180136/http://livertox.nlm.nih.gov/Ranitidine.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160828180136/http://livertox.nlm.nih.gov/Ranitidine.htm'" tppabs="https://web.archive.org/web/20160828180136/http://livertox.nlm.nih.gov/Ranitidine.htm" class="external text external">Archived</a> from the original on 28 August 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">25 August</span> 2016</span>.</cite></span></li><li id="cite_note-37"> <span id="mw-reference-text-cite_note-37" class="mw-reference-text"><cite id="CITEREFMallowRebuckOslerAhern2004" class="citation journal cs1">Mallow S, Rebuck JA, Osler T,  et al. (2004). "Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients?". <i>Curr Surg</i>. <b>61</b> (5): 452–458. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.cursur.2004.03.014  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.cursur.2004.03.014'" tppabs="https://doi.org/10.1016%2Fj.cursur.2004.03.014" class="external text external">10.1016/j.cursur.2004.03.014</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15475094  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15475094'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15475094" class="external text external">15475094</a>.</cite></span></li><li id="cite_note-pmid16651285-38"> <span id="mw-reference-text-cite_note-pmid16651285-38" class="mw-reference-text"><cite id="CITEREFCananiCirilloRoggeroRomano2006" class="citation journal cs1">Canani RB, Cirillo P, Roggero P,  et al. (May 2006). "Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children". <i>Pediatrics</i>. <b>117</b> (5): e817–20. doi:<a href="javascript:if(confirm('https://doi.org/10.1542%2Fpeds.2005-1655  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1542%2Fpeds.2005-1655'" tppabs="https://doi.org/10.1542%2Fpeds.2005-1655" class="external text external">10.1542/peds.2005-1655</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16651285  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16651285'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16651285" class="external text external">16651285</a>.</cite></span></li><li id="cite_note-pmid21455428-39"> <span id="mw-reference-text-cite_note-pmid21455428-39" class="mw-reference-text"><cite id="CITEREFBangiaKamathMohan2011" class="citation journal cs1">Bangia AV, Kamath N, Mohan V (2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062128  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062128'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062128" class="external text external">"Ranitidine-induced thrombocytopenia: A rare drug reaction"</a>. <i>Indian J Pharmacol</i>. <b>43</b> (1): 76–7. doi:<a href="javascript:if(confirm('https://doi.org/10.4103%2F0253-7613.75676  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4103%2F0253-7613.75676'" tppabs="https://doi.org/10.4103%2F0253-7613.75676" class="external text external">10.4103/0253-7613.75676</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062128  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062128'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062128" class="external text external">3062128</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21455428  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21455428'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21455428" class="external text external">21455428</a>.</cite></span></li><li id="cite_note-40"> <span id="mw-reference-text-cite_note-40" class="mw-reference-text"><cite class="citation web cs1"><span class="cs1-lock-subscription"><a href="javascript:if(confirm('http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613#f_warnings-and-precautions'" tppabs="http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613#f_warnings-and-precautions" class="external text external">"Ranitidine drug information"</a></span>. Lexicomp. <a href="javascript:if(confirm('https://web.archive.org/web/20140420014925/http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140420014925/http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613#f_warnings-and-precautions'" tppabs="https://web.archive.org/web/20140420014925/http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613#f_warnings-and-precautions" class="external text external">Archived</a> from the original on 20 April 2014.</cite></span></li><li id="cite_note-41"> <span id="mw-reference-text-cite_note-41" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.bfarm.de/SharedDocs/Downloads/EN/Drugs/vigilance/PSURs/csp/q-u/ranitidine.pdf?__blob=publicationFile&v=4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.bfarm.de/SharedDocs/Downloads/EN/Drugs/vigilance/PSURs/csp/q-u/ranitidine.pdf?__blob=publicationFile&v=4'" tppabs="https://www.bfarm.de/SharedDocs/Downloads/EN/Drugs/vigilance/PSURs/csp/q-u/ranitidine.pdf?__blob=publicationFile&v=4" class="external text external">"Ranitidine - core safety profile"</a> <span class="cs1-format">(PDF)</span>. <i>Bundesinstitut für Arzneimittel und MedizinProdukte</i>.</cite></span></li><li id="cite_note-42"> <span id="mw-reference-text-cite_note-42" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613#f_pregnancy-and-lactation'" tppabs="http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613#f_pregnancy-and-lactation" class="external text external">"Ranitidine"</a>. Lexicomp. <a href="javascript:if(confirm('https://web.archive.org/web/20140420014925/http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140420014925/http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613#f_pregnancy-and-lactation'" tppabs="https://web.archive.org/web/20140420014925/http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7613#f_pregnancy-and-lactation" class="external text external">Archived</a> from the original on 20 April 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">19 April</span> 2014</span>.</cite></span></li><li id="cite_note-43"> <span id="mw-reference-text-cite_note-43" class="mw-reference-text"><cite class="citation journal cs1">Canani RB, Cirillo P, Roggero P,  et al. (2006). "Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children". <i>Pediatrics</i>. <b>117</b> (5): e817–20. doi:<a href="javascript:if(confirm('https://doi.org/10.1542%2Fpeds.2005-1655  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1542%2Fpeds.2005-1655'" tppabs="https://doi.org/10.1542%2Fpeds.2005-1655" class="external text external">10.1542/peds.2005-1655</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16651285  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16651285'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16651285" class="external text external">16651285</a>.</cite></span></li><li id="cite_note-44"> <span id="mw-reference-text-cite_note-44" class="mw-reference-text"><cite id="CITEREFGuilletStollCottenGantz2006" class="citation journal cs1">Guillet R, Stoll BJ, Cotten CM,  et al. (2006). <a href="javascript:if(confirm('https://doi.org/10.1542/peds.2005-1543  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1542/peds.2005-1543'" tppabs="https://doi.org/10.1542/peds.2005-1543" class="external text external">"Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants"</a>. <i>Pediatrics</i>. <b>117</b> (2): e137–42. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1542%2Fpeds.2005-1543  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1542%2Fpeds.2005-1543'" tppabs="https://doi.org/10.1542%2Fpeds.2005-1543" class="external text external">10.1542/peds.2005-1543</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16390920  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16390920'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16390920" class="external text external">16390920</a>.</cite></span></li><li id="cite_note-45"> <span id="mw-reference-text-cite_note-45" class="mw-reference-text"><cite id="CITEREFTerrinPassarielloDe_CurtisManguso2012" class="citation journal cs1">Terrin G, Passariello A, De Curtis M,  et al. (2012). <a href="javascript:if(confirm('https://doi.org/10.1542/peds.2011-0796  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1542/peds.2011-0796'" tppabs="https://doi.org/10.1542/peds.2011-0796" class="external text external">"Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns"</a>. <i>Pediatrics</i>. <b>129</b> (1): 40–5. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1542%2Fpeds.2011-0796  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1542%2Fpeds.2011-0796'" tppabs="https://doi.org/10.1542%2Fpeds.2011-0796" class="external text external">10.1542/peds.2011-0796</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22157140  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22157140'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22157140" class="external text external">22157140</a>.</cite></span></li><li id="cite_note-46"> <span id="mw-reference-text-cite_note-46" class="mw-reference-text"><cite id="CITEREFBrahmYeagerFoxFarmer2010" class="citation journal cs1">Brahm NC, Yeager LL, Fox MD,  et al. (15 August 2010). <a href="javascript:if(confirm('http://pdfs.semanticscholar.org/ce3a/6ae9c80fac1f557889fdda9cfce13dd3a203.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://pdfs.semanticscholar.org/ce3a/6ae9c80fac1f557889fdda9cfce13dd3a203.pdf'" tppabs="http://pdfs.semanticscholar.org/ce3a/6ae9c80fac1f557889fdda9cfce13dd3a203.pdf" class="external text external">"Commonly prescribed medications and potential false-positive urine drug screens"</a> <span class="cs1-format">(PDF)</span>. <i>Am J Health Syst Pharm</i>. <b>67</b> (16): 1344–1350. doi:<a href="javascript:if(confirm('https://doi.org/10.2146%2Fajhp090477  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2146%2Fajhp090477'" tppabs="https://doi.org/10.2146%2Fajhp090477" class="external text external">10.2146/ajhp090477</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20689123  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20689123'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20689123" class="external text external">20689123</a>.</cite></span></li><li id="cite_note-47"> <span id="mw-reference-text-cite_note-47" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/medical-product-safety-information/zantac-ranitidine-safety-information-ndma-found-samples-some-ranitidine-medicines  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/medical-product-safety-information/zantac-ranitidine-safety-information-ndma-found-samples-some-ranitidine-medicines'" tppabs="https://www.fda.gov/safety/medical-product-safety-information/zantac-ranitidine-safety-information-ndma-found-samples-some-ranitidine-medicines" class="external text external">"Zantac (ranitidine): Safety Information - NDMA Found in Samples of Some Ranitidine Medicines"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 12 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">6 May</span> 2020</span>.</cite></span></li><li id="cite_note-Health_Canada-48"> <span id="mw-reference-text-cite_note-Health_Canada-48" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71029a-eng.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71029a-eng.php'" tppabs="https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71029a-eng.php" class="external text external">"Health Canada requests that companies stop distributing ranitidine drugs in Canada while it assesses NDMA; additional products being recalled - Recalls and safety alerts"</a>. <i>Health Canada</i>. 26 September 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190926211509/https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71029a-eng.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190926211509/https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71029a-eng.php'" tppabs="https://web.archive.org/web/20190926211509/https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71029a-eng.php" class="external text external">Archived</a> from the original on 26 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">26 September</span> 2019</span>.</cite></span></li><li id="cite_note-EMA2-49"> <span id="mw-reference-text-cite_note-EMA2-49" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/news/ema-review-ranitidine-medicines-following-detection-ndma  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/news/ema-review-ranitidine-medicines-following-detection-ndma'" tppabs="https://www.ema.europa.eu/en/news/ema-review-ranitidine-medicines-following-detection-ndma" class="external text external">"EMA to review ranitidine medicines following detection of NDMA"</a>. <i>European Medicines Agency (EMA)</i> (Press release). 13 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">19 September</span> 2019</span>.</cite></span></li><li id="cite_note-SandozStop-50"> <span id="mw-reference-text-cite_note-SandozStop-50" class="mw-reference-text"><cite id="CITEREFBomey2019" class="citation news cs1">Bomey N (19 September 2019). <a href="javascript:if(confirm('https://www.usatoday.com/story/money/2019/09/19/generic-zantac-ranitidine-sandoz-distribution-stop-novartis/2372161001/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.usatoday.com/story/money/2019/09/19/generic-zantac-ranitidine-sandoz-distribution-stop-novartis/2372161001/'" tppabs="https://www.usatoday.com/story/money/2019/09/19/generic-zantac-ranitidine-sandoz-distribution-stop-novartis/2372161001/" class="external text external">"Ranitidine warnings: Generic Zantac distribution halted on cancer fear"</a>. <i>USA Today</i><span class="reference-accessdate">. Retrieved <span class="nowrap">20 September</span> 2019</span>.</cite></span></li><li id="cite_note-51"> <span id="mw-reference-text-cite_note-51" class="mw-reference-text"><cite id="CITEREFPalmer2019" class="citation web cs1">Palmer E (19 September 2019). <a href="javascript:if(confirm('https://www.fiercepharma.com/manufacturing/novartis-doesn-t-wait-for-fda-investigation-and-halts-distribution-its-generic-zantac  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fiercepharma.com/manufacturing/novartis-doesn-t-wait-for-fda-investigation-and-halts-distribution-its-generic-zantac'" tppabs="https://www.fiercepharma.com/manufacturing/novartis-doesn-t-wait-for-fda-investigation-and-halts-distribution-its-generic-zantac" class="external text external">"Novartis doesn't wait for FDA investigation and halts distribution of its generic Zantac"</a>. <i>FiercePharma</i><span class="reference-accessdate">. Retrieved <span class="nowrap">20 September</span> 2019</span>. <q>Novartis on Wednesday said it was stopping worldwide distribution of its generic versions of the antacid while regulators investigate the fact that the impurity N-nitrosodimethylamine (NDMA) has been detected these ranitidine-based drugs.</q></cite></span></li><li id="cite_note-52"> <span id="mw-reference-text-cite_note-52" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.in-pharmatechnologist.com/Article/2019/09/19/Sandoz-ceases-distribution-of-ranitidine-product  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.in-pharmatechnologist.com/Article/2019/09/19/Sandoz-ceases-distribution-of-ranitidine-product'" tppabs="https://www.in-pharmatechnologist.com/Article/2019/09/19/Sandoz-ceases-distribution-of-ranitidine-product" class="external text external">"Sandoz ceases distribution of ranitidine product"</a>. <i>Pharmaceutical news, Pharma industry, Pharmaceutical manufacturing</i>. 19 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">24 September</span> 2019</span>.</cite></span></li><li id="cite_note-53"> <span id="mw-reference-text-cite_note-53" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.in-pharmatechnologist.com/Article/2019/09/24/Sandoz-expands-recall-of-antacid  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.in-pharmatechnologist.com/Article/2019/09/24/Sandoz-expands-recall-of-antacid'" tppabs="https://www.in-pharmatechnologist.com/Article/2019/09/24/Sandoz-expands-recall-of-antacid" class="external text external">"Sandoz expands recall of antacid"</a>. <i>Pharmaceutical news, Pharma industry, Pharmaceutical manufacturing</i>. 24 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">24 September</span> 2019</span>.</cite></span></li><li id="cite_note-54"> <span id="mw-reference-text-cite_note-54" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.prnewswire.com/news-releases/sandoz-inc-issues-voluntary-recall-of-ranitidine-hydrochloride-capsules-150mg-and-300mg-due-to-an-elevated-amount-of-unexpected-impurity-n-nitrosodimethylamine-ndma-in-the-product-300923689.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.prnewswire.com/news-releases/sandoz-inc-issues-voluntary-recall-of-ranitidine-hydrochloride-capsules-150mg-and-300mg-due-to-an-elevated-amount-of-unexpected-impurity-n-nitrosodimethylamine-ndma-in-the-product-300923689.html'" tppabs="https://www.prnewswire.com/news-releases/sandoz-inc-issues-voluntary-recall-of-ranitidine-hydrochloride-capsules-150mg-and-300mg-due-to-an-elevated-amount-of-unexpected-impurity-n-nitrosodimethylamine-ndma-in-the-product-300923689.html" class="external text external">"Sandoz Inc. issues voluntary recall of Ranitidine Hydrochloride capsules 150mg and 300mg due to an elevated amount of unexpected impurity, N-nitrosodimethylamine (NDMA), in the product"</a> (Press release). Sandoz Inc. 23 September 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190924172401/https://www.prnewswire.com/news-releases/sandoz-inc-issues-voluntary-recall-of-ranitidine-hydrochloride-capsules-150mg-and-300mg-due-to-an-elevated-amount-of-unexpected-impurity-n-nitrosodimethylamine-ndma-in-the-product-300923689.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190924172401/https://www.prnewswire.com/news-releases/sandoz-inc-issues-voluntary-recall-of-ranitidine-hydrochloride-capsules-150mg-and-300mg-due-to-an-elevated-amount-of-unexpected-impurity-n-nitrosodimethylamine-ndma-in-the-product-300923689.html'" tppabs="https://web.archive.org/web/20190924172401/https://www.prnewswire.com/news-releases/sandoz-inc-issues-voluntary-recall-of-ranitidine-hydrochloride-capsules-150mg-and-300mg-due-to-an-elevated-amount-of-unexpected-impurity-n-nitrosodimethylamine-ndma-in-the-product-300923689.html" class="external text external">Archived</a> from the original on 24 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">24 September</span> 2019</span> <span>–</span> via PR Newswire.</cite></span></li><li id="cite_note-55"> <span id="mw-reference-text-cite_note-55" class="mw-reference-text"><cite id="CITEREFThomas2019" class="citation news cs1">Thomas K (19 September 2019). <a href="javascript:if(confirm('https://www.nytimes.com/2019/09/19/health/zantac-recall.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2019/09/19/health/zantac-recall.html'" tppabs="https://www.nytimes.com/2019/09/19/health/zantac-recall.html" class="external text external">"Should you keep taking Zantac for your heartburn?"</a>. <i>The New York Times</i><span class="reference-accessdate">. Retrieved <span class="nowrap">24 September</span> 2019</span>.</cite></span></li><li id="cite_note-56"> <span id="mw-reference-text-cite_note-56" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.latimes.com/business/story/2019-09-18/carcinogen-scare-tainted-zantac  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.latimes.com/business/story/2019-09-18/carcinogen-scare-tainted-zantac'" tppabs="https://www.latimes.com/business/story/2019-09-18/carcinogen-scare-tainted-zantac" class="external text external">"Carcinogen scare sets off global race to contain tainted Zantac"</a>. <i>Los Angeles Times</i>. 18 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">24 September</span> 2019</span>.</cite></span></li><li id="cite_note-57"> <span id="mw-reference-text-cite_note-57" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.aifa.gov.it/-/comunicazione-aifa-sui-farmaci-contenenti-ranitidina  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.aifa.gov.it/-/comunicazione-aifa-sui-farmaci-contenenti-ranitidina'" tppabs="https://www.aifa.gov.it/-/comunicazione-aifa-sui-farmaci-contenenti-ranitidina" class="external text external">"Comunicazione AIFA sui farmaci contenenti ranitidina"</a>. <i>Agenzia Italiana del Farmaco</i> (in Italian). Rome, Italy<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>.</cite></span></li><li id="cite_note-58"> <span id="mw-reference-text-cite_note-58" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.abda.de/fuer-apotheker/arzneimittelkommission/amk-nachrichten/detail/online-nachricht-amk-liste-der-chargen-rueckrufe-ranitidin-haltiger-arzneimittel/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.abda.de/fuer-apotheker/arzneimittelkommission/amk-nachrichten/detail/online-nachricht-amk-liste-der-chargen-rueckrufe-ranitidin-haltiger-arzneimittel/'" tppabs="https://www.abda.de/fuer-apotheker/arzneimittelkommission/amk-nachrichten/detail/online-nachricht-amk-liste-der-chargen-rueckrufe-ranitidin-haltiger-arzneimittel/" class="external text external">"Online Nachricht: AMK: Liste der (Chargen-)Rückrufe Ranitidin-haltiger Arzneimittel"</a>. <i>Arzneimittelkommission der Deutschen Apotheker (AMK)</i> (in German). 17 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">20 March</span> 2020</span>.</cite></span></li><li id="cite_note-59"> <span id="mw-reference-text-cite_note-59" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.tga.gov.au/alert/ranitidine-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.tga.gov.au/alert/ranitidine-0'" tppabs="https://www.tga.gov.au/alert/ranitidine-0" class="external text external">"Ranitidine"</a>. <i>Therapeutic Goods Administration (TGA)</i>. 17 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">19 October</span> 2019</span>.</cite></span></li><li id="cite_note-60"> <span id="mw-reference-text-cite_note-60" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-ranitidine-tablets-75mg-and-150mg-all-pack-sizes-and  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-ranitidine-tablets-75mg-and-150mg-all-pack-sizes-and'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-ranitidine-tablets-75mg-and-150mg-all-pack-sizes-and" class="external text external">"Apotex Corp. issues voluntary nationwide recall of Ranitidine tablets 75mg and 150mg (all pack sizes and formats) due to the potential for detection of an amount of unexpected impurity, N-nitrosodimethylamine (NDMA) impurity in the product"</a>. <i>U.S. Food and Drug Administration</i>. 26 September 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190926201621/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-ranitidine-tablets-75mg-and-150mg-all-pack-sizes-and  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190926201621/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-ranitidine-tablets-75mg-and-150mg-all-pack-sizes-and'" tppabs="https://web.archive.org/web/20190926201621/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-ranitidine-tablets-75mg-and-150mg-all-pack-sizes-and" class="external text external">Archived</a> from the original on 26 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">26 September</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-61"> <span id="mw-reference-text-cite_note-61" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.upi.com/Top_News/US/2019/09/30/Heartburn-drug-recalled-removed-from-shelves-over-cancer-concerns/7811569853996/?sl=7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.upi.com/Top_News/US/2019/09/30/Heartburn-drug-recalled-removed-from-shelves-over-cancer-concerns/7811569853996/?sl=7'" tppabs="https://www.upi.com/Top_News/US/2019/09/30/Heartburn-drug-recalled-removed-from-shelves-over-cancer-concerns/7811569853996/?sl=7" class="external text external">"Heartburn drug recalled, removed from shelves over cancer concerns"</a>. <i>United Press International</i>. 30 September 2019.</cite></span></li><li id="cite_note-62"> <span id="mw-reference-text-cite_note-62" class="mw-reference-text"><cite id="CITEREFGarcia2019" class="citation news cs1">Garcia SE (30 September 2019). <a href="javascript:if(confirm('https://www.nytimes.com/2019/09/30/health/zantac-recall-cancer.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2019/09/30/health/zantac-recall-cancer.html'" tppabs="https://www.nytimes.com/2019/09/30/health/zantac-recall-cancer.html" class="external text external">"Zantac pulled from shelves by Walgreens, Rite Aid and CVS over carcinogen fears"</a>. <i>The New York Times</i><span class="reference-accessdate">. Retrieved <span class="nowrap">3 October</span> 2019</span>.</cite></span></li><li id="cite_note-63"> <span id="mw-reference-text-cite_note-63" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://cvshealth.com/newsroom/press-releases/cvs-pharmacy-statement-regarding-zantac-and-other-ranitidine-products  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://cvshealth.com/newsroom/press-releases/cvs-pharmacy-statement-regarding-zantac-and-other-ranitidine-products'" tppabs="https://cvshealth.com/newsroom/press-releases/cvs-pharmacy-statement-regarding-zantac-and-other-ranitidine-products" class="external text external">"CVS pharmacy statement regarding Zantac and other Ranitidine products"</a>. <i>CVS Health</i>. 3 October 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191003092104/https://cvshealth.com/newsroom/press-releases/cvs-pharmacy-statement-regarding-zantac-and-other-ranitidine-products  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191003092104/https://cvshealth.com/newsroom/press-releases/cvs-pharmacy-statement-regarding-zantac-and-other-ranitidine-products'" tppabs="https://web.archive.org/web/20191003092104/https://cvshealth.com/newsroom/press-releases/cvs-pharmacy-statement-regarding-zantac-and-other-ranitidine-products" class="external text external">Archived</a> from the original on 3 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">3 October</span> 2019</span>.</cite></span></li><li id="cite_note-64"> <span id="mw-reference-text-cite_note-64" class="mw-reference-text"><cite id="CITEREFKazin2019" class="citation news cs1">Kazin M (2 October 2019). <a href="javascript:if(confirm('https://www.foxbusiness.com/markets/walmart-suspends-sale-of-zantac-other-products-containing-ranitidine-over-cancer-risk  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.foxbusiness.com/markets/walmart-suspends-sale-of-zantac-other-products-containing-ranitidine-over-cancer-risk'" tppabs="https://www.foxbusiness.com/markets/walmart-suspends-sale-of-zantac-other-products-containing-ranitidine-over-cancer-risk" class="external text external">"Walmart suspends sale of Zantac, other products containing ranitidine over cancer risk"</a>. <i>Fox Business</i><span class="reference-accessdate">. Retrieved <span class="nowrap">3 October</span> 2019</span>.</cite></span></li><li id="cite_note-65"> <span id="mw-reference-text-cite_note-65" class="mw-reference-text"><cite id="CITEREFCriss2019" class="citation news cs1">Criss D (30 September 2019). <a href="javascript:if(confirm('https://www.cnn.com/2019/09/30/health/cvs-zantac-pulled-cancer-trnd/index.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.cnn.com/2019/09/30/health/cvs-zantac-pulled-cancer-trnd/index.html'" tppabs="https://www.cnn.com/2019/09/30/health/cvs-zantac-pulled-cancer-trnd/index.html" class="external text external">"Walmart, CVS, Walgreens pull Zantac and similar heartburn drugs because of cancer worries"</a>. <i>CNN</i><span class="reference-accessdate">. Retrieved <span class="nowrap">3 October</span> 2019</span>.</cite></span></li><li id="cite_note-66"> <span id="mw-reference-text-cite_note-66" class="mw-reference-text"><cite id="CITEREFEdney2019" class="citation news cs1">Edney A (30 September 2019). <a href="javascript:if(confirm('https://www.bloomberg.com/news/articles/2019-09-30/walgreens-cvs-take-zantac-off-shelves-as-carcinogen-probed  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.bloomberg.com/news/articles/2019-09-30/walgreens-cvs-take-zantac-off-shelves-as-carcinogen-probed'" tppabs="https://www.bloomberg.com/news/articles/2019-09-30/walgreens-cvs-take-zantac-off-shelves-as-carcinogen-probed" class="external text external">"Major U.S. drugstore chains pull Zantac amid carcinogen concern"</a>. <i>Bloomberg</i><span class="reference-accessdate">. Retrieved <span class="nowrap">3 October</span> 2019</span>.</cite></span></li><li id="cite_note-67"> <span id="mw-reference-text-cite_note-67" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan'" tppabs="https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan" class="external text external">"FDA updates and press announcements on Angiotensin II Receptor Blocker (ARB) recalls (Valsartan, Losartan, and Irbesartan)"</a>. <i>U.S. Food and Drug Administration</i>. 20 September 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191003024610/https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191003024610/https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan'" tppabs="https://web.archive.org/web/20191003024610/https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan" class="external text external">Archived</a> from the original on 3 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">2 October</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-68"> <span id="mw-reference-text-cite_note-68" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/media/130801/download  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/media/130801/download'" tppabs="https://www.fda.gov/media/130801/download" class="external text external">"Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) method for the determination of NDMA in Ranitidine drug substance and drug product"</a> <span class="cs1-format">(PDF)</span>. <i>U.S. Food and Drug Administration</i>. FY19-177-DP A-S. <a href="javascript:if(confirm('https://web.archive.org/web/20191102045002/https://www.fda.gov/media/130801/download  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191102045002/https://www.fda.gov/media/130801/download'" tppabs="https://web.archive.org/web/20191102045002/https://www.fda.gov/media/130801/download" class="external text external">Archived</a> from the original on 2 November 2019.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-69"> <span id="mw-reference-text-cite_note-69" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/media/131868/download  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/media/131868/download'" tppabs="https://www.fda.gov/media/131868/download" class="external text external">"Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method for the determination of NDMA in Ranitidine drug substance and solid dosage drug product"</a> <span class="cs1-format">(PDF)</span>. <i>U.S. Food and Drug Administration</i>. 17 October 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191102041800/https://www.fda.gov/media/131868/download  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191102041800/https://www.fda.gov/media/131868/download'" tppabs="https://web.archive.org/web/20191102041800/https://www.fda.gov/media/131868/download" class="external text external">Archived</a> from the original on 2 November 2019.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-GSK-UK-70"> <span id="mw-reference-text-cite_note-GSK-UK-70" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://gskpro.com/en-gb/supply/zantac-recall/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://gskpro.com/en-gb/supply/zantac-recall/'" tppabs="https://gskpro.com/en-gb/supply/zantac-recall/" class="external text external">"Zantac recall – UK recall of Zantac (Ranitidine API), incl. Zantac Injection, Zantac Tablets, Zantac Syrup"</a>. <i>GlaxoSmithKline UK Limited</i>. Brentford, Middlesex, United Kingdom. October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>.</cite></span></li><li id="cite_note-71"> <span id="mw-reference-text-cite_note-71" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-zantac-injection-50mg-2ml-zantac-syrup-150mg-10ml-zantac-tablets-150mg-zantac-tablets-300mg-el-19-a-24  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-zantac-injection-50mg-2ml-zantac-syrup-150mg-10ml-zantac-tablets-150mg-zantac-tablets-300mg-el-19-a-24'" tppabs="https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-zantac-injection-50mg-2ml-zantac-syrup-150mg-10ml-zantac-tablets-150mg-zantac-tablets-300mg-el-19-a-24" class="external text external">"Class 2 Medicines recall: Zantac Injection 50mg/2ml, Zantac Syrup 150mg/10ml, Zantac Tablets 150mg, Zantac Tablets 300mg (EL (19)A 24)"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 8 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>GlaxoSmithKline, trading as Glaxo Welcome Ltd, is recalling all unexpired stock of Zantac (ranitidine hydrochloride) prescription only medicines (POM) from pharmacies.</q></cite></span></li><li id="cite_note-72"> <span id="mw-reference-text-cite_note-72" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/government/news/zantac-mhra-drug-alert-issued-as-glaxosmithkline-recalls-all-unexpired-stock  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/government/news/zantac-mhra-drug-alert-issued-as-glaxosmithkline-recalls-all-unexpired-stock'" tppabs="https://www.gov.uk/government/news/zantac-mhra-drug-alert-issued-as-glaxosmithkline-recalls-all-unexpired-stock" class="external text external">"Press release – Zantac – MHRA drug alert issued as GlaxoSmithKline recalls all unexpired stock"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 8 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>The MHRA has issued an alert to healthcare professionals, as GlaxoSmithKline is recalling all unexpired stock of four types of Zantac, the medicine used to treat conditions such as heartburn and stomach ulcers.</q></cite></span></li><li id="cite_note-73"> <span id="mw-reference-text-cite_note-73" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-effervescent-tablets-150mg-ranitidine-effervescent-tablets-300mg-el-19-a-27  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-effervescent-tablets-150mg-ranitidine-effervescent-tablets-300mg-el-19-a-27'" tppabs="https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-effervescent-tablets-150mg-ranitidine-effervescent-tablets-300mg-el-19-a-27" class="external text external">"Class 2 Medicines recall: Ranitidine Effervescent Tablets 150mg, Ranitidine Effervescent Tablets 300mg (EL (19)A/27)"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 17 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>Teva UK Limited trading as ratiopharm GmbH is recalling all unexpired stock of Ranitidine Effervescent Tablets from pharmacies.</q></cite></span></li><li id="cite_note-74"> <span id="mw-reference-text-cite_note-74" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/government/news/ranitidine-mhra-drug-alert-issued-for-teva-uk-recall  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/government/news/ranitidine-mhra-drug-alert-issued-for-teva-uk-recall'" tppabs="https://www.gov.uk/government/news/ranitidine-mhra-drug-alert-issued-for-teva-uk-recall" class="external text external">"Press release – Ranitidine – MHRA drug alert issued for Teva UK recall"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 17 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>Teva UK Ltd is recalling unexpired stock of certain batches of 2 types of Ranitidine medicines used to treat conditions such as heartburn and stomach ulcers.</q></cite></span></li><li id="cite_note-75"> <span id="mw-reference-text-cite_note-75" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-150mg-10ml-oral-solution-el-19-a-29  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-150mg-10ml-oral-solution-el-19-a-29'" tppabs="https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-150mg-10ml-oral-solution-el-19-a-29" class="external text external">"Class 2 Medicines recall: Ranitidine 150mg/10ml Oral Solution (EL (19)A/29)"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 25 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>Rosemont Pharmaceuticals Limited is recalling unexpired stock from pharmacies as a precautionary measure due to possible contamination with an impurity.</q></cite></span></li><li id="cite_note-76"> <span id="mw-reference-text-cite_note-76" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-zantac-75-relief-tablets-zantac-75-tablets-galpharm-indigestion-relief-75mg-tablets-boots-heartburn-indigestion-relief-75mg-tablets-kirkland-indigestion-relief-75mg-tablets-morrisons-indigestion-heartburn-  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-zantac-75-relief-tablets-zantac-75-tablets-galpharm-indigestion-relief-75mg-tablets-boots-heartburn-indigestion-relief-75mg-tablets-kirkland-indigestion-relief-75mg-tablets-morrisons-indigestion-heartburn-'" tppabs="https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-zantac-75-relief-tablets-zantac-75-tablets-galpharm-indigestion-relief-75mg-tablets-boots-heartburn-indigestion-relief-75mg-tablets-kirkland-indigestion-relief-75mg-tablets-morrisons-indigestion-heartburn-" class="external text external">"Class 2 Medicines recall: Zantac 75 Relief Tablets, Zantac 75 Tablets, Galpharm Indigestion Relief 75mg Tablets, Boots Heartburn &amp; Indigestion Relief 75mg Tablets, Kirkland Indigestion Relief 75mg Tablets, Morrisons Indigestion &amp; Heartburn Relief 75mg Tablets, Boots Heartburn &amp; Indigestion Relief 75mg Tablets (EL (19)A/30)"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 25 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>Omega Pharma Limited and Galpharm International Limited are recalling unexpired stock from pharmacies and retail stores as a precautionary measure due to possible contamination with an impurity.</q></cite></span></li><li id="cite_note-77"> <span id="mw-reference-text-cite_note-77" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/government/news/ranitidine-mhra-drug-alerts-issued-as-perrigo-recalls-prescription-only-and-over-the-counter-products  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/government/news/ranitidine-mhra-drug-alerts-issued-as-perrigo-recalls-prescription-only-and-over-the-counter-products'" tppabs="https://www.gov.uk/government/news/ranitidine-mhra-drug-alerts-issued-as-perrigo-recalls-prescription-only-and-over-the-counter-products" class="external text external">"Press release – Ranitidine – MHRA drug alerts issued as Perrigo recalls prescription only and over-the-counter products"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 25 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>The MHRA has issued alerts to healthcare professionals and retailers, as Perrigo Company plc is recalling all unexpired stock of certain batches of Ranitidine medicines used to treat conditions such as heartburn and stomach ulcers.</q></cite></span></li><li id="cite_note-78"> <span id="mw-reference-text-cite_note-78" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-oral-solution-30mg-ml-pl-31862-0023-ranitidine-150mg-tablets-pl-11311-0138-el-19-a-36  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-oral-solution-30mg-ml-pl-31862-0023-ranitidine-150mg-tablets-pl-11311-0138-el-19-a-36'" tppabs="https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-oral-solution-30mg-ml-pl-31862-0023-ranitidine-150mg-tablets-pl-11311-0138-el-19-a-36" class="external text external">"Class 2 Medicines Recall: Ranitidine Oral Solution 30mg/ml, PL 31862/0023, Ranitidine 150mg Tablets, PL 11311/0138 (EL(19)A/36)"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 19 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>Creo Pharma Limited and Tillomed Laboratories Limited are recalling all unexpired stock of the products listed in this alert.</q></cite></span></li><li id="cite_note-79"> <span id="mw-reference-text-cite_note-79" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/government/news/ranitidine-oral-solution-and-tablets-recall  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/government/news/ranitidine-oral-solution-and-tablets-recall'" tppabs="https://www.gov.uk/government/news/ranitidine-oral-solution-and-tablets-recall" class="external text external">"Press release – Ranitidine Oral Solution and Tablets recall"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 19 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>Ranitidine – MHRA drug alert issued as Creo Pharma Limited and Tillomed Laboratories recall unexpired stock.</q></cite></span></li><li id="cite_note-80"> <span id="mw-reference-text-cite_note-80" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-75mg-tablets-various-liveries-el-19-a-37  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-75mg-tablets-various-liveries-el-19-a-37'" tppabs="https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-75mg-tablets-various-liveries-el-19-a-37" class="external text external">"Class 2 Medicines recall: Ranitidine 75mg Tablets, (various liveries) (EL(19)A/37)"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 21 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>OTC Concepts Ltd, Relonchem Ltd, Noumed Life Sciences Ltd and Medreich Plc. are recalling stock from pharmacies and retail stores as a precautionary measure due to possible contamination with an impurity.</q></cite></span></li><li id="cite_note-81"> <span id="mw-reference-text-cite_note-81" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/government/news/mhra-drug-alert-recalls-for-13-over-the-counter-ranitidine-medicines  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/government/news/mhra-drug-alert-recalls-for-13-over-the-counter-ranitidine-medicines'" tppabs="https://www.gov.uk/government/news/mhra-drug-alert-recalls-for-13-over-the-counter-ranitidine-medicines" class="external text external">"Press release – MHRA drug alert: recalls for 13 over-the-counter Ranitidine medicines"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 21 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>A drug alert has been issued to retailers and healthcare professionals as 4 companies are recalling batches of certain over-the-counter Ranitidine medicines used to treat conditions such as stomach ulcers and heartburn.</q></cite></span></li><li id="cite_note-82"> <span id="mw-reference-text-cite_note-82" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-150mg-film-coated-tablets-pl-20075-0063-ranitidine-300mg-film-coated-tablets-pl-20075-0064-el-19-a-40  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-150mg-film-coated-tablets-pl-20075-0063-ranitidine-300mg-film-coated-tablets-pl-20075-0064-el-19-a-40'" tppabs="https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-150mg-film-coated-tablets-pl-20075-0063-ranitidine-300mg-film-coated-tablets-pl-20075-0064-el-19-a-40" class="external text external">"Class 2 Medicines recall: Ranitidine 150mg Film-Coated Tablets, PL 20075/0063, Ranitidine 300mg Film-Coated Tablets, PL 20075/0064 (EL(19)A/40)"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 5 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>Accord Healthcare are recalling all unexpired stock of the below products from pharmacies and retail stores as a precautionary measure.</q></cite></span></li><li id="cite_note-83"> <span id="mw-reference-text-cite_note-83" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-medley-pharma-limited-ranitidine-150mg-tablets-bp-pl-43870-0026-ranitidine-300mg-tablets-bp-pl-43870-0027-el-19-a-41  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-medley-pharma-limited-ranitidine-150mg-tablets-bp-pl-43870-0026-ranitidine-300mg-tablets-bp-pl-43870-0027-el-19-a-41'" tppabs="https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-medley-pharma-limited-ranitidine-150mg-tablets-bp-pl-43870-0026-ranitidine-300mg-tablets-bp-pl-43870-0027-el-19-a-41" class="external text external">"Class 2 Medicines Recall: Medley Pharma Limited, Ranitidine 150mg Tablets BP, PL 43870/0026, Ranitidine 300mg Tablets BP, PL 43870/0027 (EL(19)A/41)"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 16 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>Medley Pharma Limited is recalling all unexpired stock of the below products from pharmacies and retail stores as a precautionary measure.</q></cite></span></li><li id="cite_note-84"> <span id="mw-reference-text-cite_note-84" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-medreich-plc-ranitidine-150mg-tablets-pl-21880-0091-ranitidine-300mg-tablets-pl-21880-0092-el-20-a-05  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-medreich-plc-ranitidine-150mg-tablets-pl-21880-0091-ranitidine-300mg-tablets-pl-21880-0092-el-20-a-05'" tppabs="https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-medreich-plc-ranitidine-150mg-tablets-pl-21880-0091-ranitidine-300mg-tablets-pl-21880-0092-el-20-a-05" class="external text external">"Class 2 Medicines recall: Medreich PLC, Ranitidine 150mg Tablets, PL 21880/0091, Ranitidine 300mg Tablets, PL 21880/0092 (EL (20)A/05)"</a>. <i>GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 3 February 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>Medreich Plc is recalling all unexpired stock of the above products from pharmacies and wholesalers as a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.</q></cite></span></li><li id="cite_note-85"> <span id="mw-reference-text-cite_note-85" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=102904  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=102904'" tppabs="https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=102904" class="external text external">"MHRA Central Alerting System (CAS) – Ranitidine: all oral formulations.  Supply disruption"</a>. <i>CAS.MHRA.GOV.uk</i>. United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA). 15 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">30 March</span> 2020</span>. <q>All oral formulations of ranitidine are shortly anticipated to be out of stock until further notice.  This alert provides healthcare professionals with advice on the management of patients currently taking ranitidine.</q></cite></span></li><li id="cite_note-86"> <span id="mw-reference-text-cite_note-86" class="mw-reference-text"><cite class="citation news cs1">Thomas K (18 October 2019). <a href="javascript:if(confirm('https://www.nytimes.com/2019/10/18/health/zantac-recall-carcinogen-sanofi.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2019/10/18/health/zantac-recall-carcinogen-sanofi.html'" tppabs="https://www.nytimes.com/2019/10/18/health/zantac-recall-carcinogen-sanofi.html" class="external text external">"Zantac recall widens as Sanofi pulls its drug over carcinogen fears"</a>. <i>The New York Times</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 October</span> 2019</span>.</cite></span></li><li id="cite_note-87"> <span id="mw-reference-text-cite_note-87" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sanofi-provides-update-precautionary-voluntary-recall-zantac-otc-us  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sanofi-provides-update-precautionary-voluntary-recall-zantac-otc-us'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sanofi-provides-update-precautionary-voluntary-recall-zantac-otc-us" class="external text external">"Sanofi provides update on precautionary voluntary recall of Zantac OTC in U.S."</a> <i>U.S. Food and Drug Administration</i>. 23 October 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191024035253/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sanofi-provides-update-precautionary-voluntary-recall-zantac-otc-us  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191024035253/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sanofi-provides-update-precautionary-voluntary-recall-zantac-otc-us'" tppabs="https://web.archive.org/web/20191024035253/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sanofi-provides-update-precautionary-voluntary-recall-zantac-otc-us" class="external text external">Archived</a> from the original on 24 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">23 October</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-88"> <span id="mw-reference-text-cite_note-88" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/perrigo-company-plc-issues-voluntary-worldwide-recall-ranitidine-due-possible-presence-impurity-n  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/perrigo-company-plc-issues-voluntary-worldwide-recall-ranitidine-due-possible-presence-impurity-n'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/perrigo-company-plc-issues-voluntary-worldwide-recall-ranitidine-due-possible-presence-impurity-n" class="external text external">"Perrigo Company plc issues voluntary worldwide recall of Ranitidine due to possible presence of impurity, N-nitrosodimethylamine (NDMA) impurity in the product"</a>. <i>U.S. Food and Drug Administration</i>. 23 October 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191024035720/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/perrigo-company-plc-issues-voluntary-worldwide-recall-ranitidine-due-possible-presence-impurity-n  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191024035720/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/perrigo-company-plc-issues-voluntary-worldwide-recall-ranitidine-due-possible-presence-impurity-n'" tppabs="https://web.archive.org/web/20191024035720/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/perrigo-company-plc-issues-voluntary-worldwide-recall-ranitidine-due-possible-presence-impurity-n" class="external text external">Archived</a> from the original on 24 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">23 October</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-89"> <span id="mw-reference-text-cite_note-89" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dr-reddys-confirms-its-voluntary-nationwide-recall-all-ranitidine-products-us-market  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dr-reddys-confirms-its-voluntary-nationwide-recall-all-ranitidine-products-us-market'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dr-reddys-confirms-its-voluntary-nationwide-recall-all-ranitidine-products-us-market" class="external text external">"Dr. Reddy's confirms its voluntary nationwide recall of all Ranitidine products in the U.S. market"</a>. <i>U.S. Food and Drug Administration</i>. 23 October 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191024035800/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dr-reddys-confirms-its-voluntary-nationwide-recall-all-ranitidine-products-us-market  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191024035800/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dr-reddys-confirms-its-voluntary-nationwide-recall-all-ranitidine-products-us-market'" tppabs="https://web.archive.org/web/20191024035800/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dr-reddys-confirms-its-voluntary-nationwide-recall-all-ranitidine-products-us-market" class="external text external">Archived</a> from the original on 24 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">23 October</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-90"> <span id="mw-reference-text-cite_note-90" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/novitium-pharma-issues-voluntary-national-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/novitium-pharma-issues-voluntary-national-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/novitium-pharma-issues-voluntary-national-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg" class="external text external">"Novitium Pharma issues voluntary national recall of Ranitidine Hydrochloride capsules 150mg and 300mg due to an elevated amount of unexpected impurity, N-nitrosodimethylamine (NDMA)"</a>. <i>U.S. Food and Drug Administration</i>. 25 October 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191029011927/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/novitium-pharma-issues-voluntary-national-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191029011927/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/novitium-pharma-issues-voluntary-national-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg'" tppabs="https://web.archive.org/web/20191029011927/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/novitium-pharma-issues-voluntary-national-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg" class="external text external">Archived</a> from the original on 29 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">28 October</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-FDA_Statement-91"> <span id="mw-reference-text-cite_note-FDA_Statement-91" class="mw-reference-text">{{cite press release|title=Statement on new testing results, including low levels of impurities in ranitidine drugs|website=U.S. Food and Drug Administration|date=1 November 2019|url=<a href="javascript:if(confirm('https://www.fda.gov/news-events/press-announcements/statement-new-testing-results-including-low-levels-impurities-ranitidine-drugs%7Carchive-url=https://web.archive.org/web/20191102041759/https://www.fda.gov/news-events/press-announcements/statement-new-testing-results-including-low-levels-impurities-ranitidine-drugs%7Carchive-date=2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/news-events/press-announcements/statement-new-testing-results-including-low-levels-impurities-ranitidine-drugs%7Carchive-url=https://web.archive.org/web/20191102041759/https://www.fda.gov/news-events/press-announcements/statement-new-testing-results-including-low-levels-impurities-ranitidine-drugs%7Carchive-date=2'" tppabs="https://www.fda.gov/news-events/press-announcements/statement-new-testing-results-including-low-levels-impurities-ranitidine-drugs%7Carchive-url=https://web.archive.org/web/20191102041759/https://www.fda.gov/news-events/press-announcements/statement-new-testing-results-including-low-levels-impurities-ranitidine-drugs%7Carchive-date=2" class="external free external">https://www.fda.gov/news-events/press-announcements/statement-new-testing-results-including-low-levels-impurities-ranitidine-drugs%7Carchive-url=https://web.archive.org/web/20191102041759/https://www.fda.gov/news-events/press-announcements/statement-new-testing-results-including-low-levels-impurities-ranitidine-drugs%7Carchive-date=2</a> November 2019|url-status=live|access-date=1 November 2019} <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-FDA_Lab_tests-92"> <span id="mw-reference-text-cite_note-FDA_Lab_tests-92" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-ranitidine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-ranitidine'" tppabs="https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-ranitidine" class="external text external">"Laboratory tests - Ranitidine"</a>. <i>U.S. Food and Drug Administration</i>. 1 November 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191102041800/https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-ranitidine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191102041800/https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-ranitidine'" tppabs="https://web.archive.org/web/20191102041800/https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-ranitidine" class="external text external">Archived</a> from the original on 2 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">1 November</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-93"> <span id="mw-reference-text-cite_note-93" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/aurobindo-pharma-usa-inc-initiates-voluntary-nationwide-consumer-level-recall-38-lots-ranitidine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/aurobindo-pharma-usa-inc-initiates-voluntary-nationwide-consumer-level-recall-38-lots-ranitidine'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/aurobindo-pharma-usa-inc-initiates-voluntary-nationwide-consumer-level-recall-38-lots-ranitidine" class="external text external">"Aurobindo Pharma USA, Inc. initiates voluntary nationwide consumer level recall of 38 lots of Ranitidine tablets 150mg, Ranitidine capsules 150mg, Ranitidine capsules 300mg and ranitidine Syrup 15mg/mL due to the detection of NDMA (Nitrosodimethylamine) impurity"</a>. <i>U.S. Food and Drug Administration</i> (Press release). 6 November 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191111033706/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/aurobindo-pharma-usa-inc-initiates-voluntary-nationwide-consumer-level-recall-38-lots-ranitidine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191111033706/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/aurobindo-pharma-usa-inc-initiates-voluntary-nationwide-consumer-level-recall-38-lots-ranitidine'" tppabs="https://web.archive.org/web/20191111033706/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/aurobindo-pharma-usa-inc-initiates-voluntary-nationwide-consumer-level-recall-38-lots-ranitidine" class="external text external">Archived</a> from the original on 11 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">10 November</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-94"> <span id="mw-reference-text-cite_note-94" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-ranitidine-tablets-usp-150mg-and-300mg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-ranitidine-tablets-usp-150mg-and-300mg'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-ranitidine-tablets-usp-150mg-and-300mg" class="external text external">"Amneal Pharmaceuticals, LLC. issues voluntary nationwide recall of Ranitidine tablets, USP, 150mg and 300mg, and Ranitidine syrup (Ranitidine Oral Solution, USP), 15 mg/mL, due to possible presence of N-nitrosodimethylamine (NDMA) impurity"</a>. <i>U.S. Food and Drug Administration</i> (Press release). 12 November 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191112234415/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-ranitidine-tablets-usp-150mg-and-300mg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191112234415/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-ranitidine-tablets-usp-150mg-and-300mg'" tppabs="https://web.archive.org/web/20191112234415/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-ranitidine-tablets-usp-150mg-and-300mg" class="external text external">Archived</a> from the original on 12 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">12 November</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-95"> <span id="mw-reference-text-cite_note-95" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/american-health-packaging-issues-voluntary-nationwide-recall-ranitidine-syrup-ranitidine-oral  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/american-health-packaging-issues-voluntary-nationwide-recall-ranitidine-syrup-ranitidine-oral'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/american-health-packaging-issues-voluntary-nationwide-recall-ranitidine-syrup-ranitidine-oral" class="external text external">"American Health Packaging issues voluntary nationwide recall of Ranitidine syrup (Ranitidine Oral Solution USP) 150 mg/10 mL liquid unit dose cups due to the detection of N-nitrosodimethylamine (NDMA) impurity"</a>. <i>U.S. Food and Drug Administration</i> (Press release). 8 November 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191112234545/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/american-health-packaging-issues-voluntary-nationwide-recall-ranitidine-syrup-ranitidine-oral  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191112234545/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/american-health-packaging-issues-voluntary-nationwide-recall-ranitidine-syrup-ranitidine-oral'" tppabs="https://web.archive.org/web/20191112234545/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/american-health-packaging-issues-voluntary-nationwide-recall-ranitidine-syrup-ranitidine-oral" class="external text external">Archived</a> from the original on 12 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">12 November</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-96"> <span id="mw-reference-text-cite_note-96" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/golden-state-medical-supply-inc-issues-voluntary-nationwide-recall-ranitidine-hydrochloride-150mg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/golden-state-medical-supply-inc-issues-voluntary-nationwide-recall-ranitidine-hydrochloride-150mg'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/golden-state-medical-supply-inc-issues-voluntary-nationwide-recall-ranitidine-hydrochloride-150mg" class="external text external">"Golden State Medical Supply, Inc. issues a voluntary nationwide recall of Ranitidine hydrochloride 150mg and 300mg capsules (manufactured by Novitium Pharma LLC) due to an elevated amount of unexpected impurity, N-nitrosodimethylamine (NDMA)"</a>. <i>U.S. Food and Drug Administration</i> (Press release). 15 November 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191123070140/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/golden-state-medical-supply-inc-issues-voluntary-nationwide-recall-ranitidine-hydrochloride-150mg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191123070140/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/golden-state-medical-supply-inc-issues-voluntary-nationwide-recall-ranitidine-hydrochloride-150mg'" tppabs="https://web.archive.org/web/20191123070140/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/golden-state-medical-supply-inc-issues-voluntary-nationwide-recall-ranitidine-hydrochloride-150mg" class="external text external">Archived</a> from the original on 23 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">22 November</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-97"> <span id="mw-reference-text-cite_note-97" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/precision-dose-inc-issues-voluntary-nationwide-recall-ranitidine-oral-solution-usp-150-mg10-ml-due  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/precision-dose-inc-issues-voluntary-nationwide-recall-ranitidine-oral-solution-usp-150-mg10-ml-due'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/precision-dose-inc-issues-voluntary-nationwide-recall-ranitidine-oral-solution-usp-150-mg10-ml-due" class="external text external">"Precision Dose Inc. issues voluntary nationwide recall of Ranitidine oral solution, USP 150 mg/10 mL due to possible presence of N-nitrosodimethylamine (NDMA) impurity"</a>. <i>U.S. Food and Drug Administration</i> (Press release). 19 November 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191123070344/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/precision-dose-inc-issues-voluntary-nationwide-recall-ranitidine-oral-solution-usp-150-mg10-ml-due  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191123070344/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/precision-dose-inc-issues-voluntary-nationwide-recall-ranitidine-oral-solution-usp-150-mg10-ml-due'" tppabs="https://web.archive.org/web/20191123070344/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/precision-dose-inc-issues-voluntary-nationwide-recall-ranitidine-oral-solution-usp-150-mg10-ml-due" class="external text external">Archived</a> from the original on 23 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">22 November</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-98"> <span id="mw-reference-text-cite_note-98" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine'" tppabs="https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine" class="external text external">"FDA updates and press announcements on NDMA in Zantac (ranitidine)"</a>. <i>U.S. Food and Drug Administration</i>. 4 December 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191206002013/https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191206002013/https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine'" tppabs="https://web.archive.org/web/20191206002013/https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine" class="external text external">Archived</a> from the original on 6 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">6 December</span> 2019</span>. <q>Today, we are announcing that we have asked manufacturers of ranitidine and nizatidine products to expand their testing for NDMA to include all lots of the medication before making them available to consumers.  If testing shows NDMA above the acceptable daily intake limit (96 nanograms per day or 0.32 parts per million for ranitidine), the manufacturer must inform the agency and should not release the lot for consumer use.</q></cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-99"> <span id="mw-reference-text-cite_note-99" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/glenmark-pharmaceuticals-inc-usa-voluntarily-recalls-all-unexpired-lots-its-ranitidine-tablets-and  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/glenmark-pharmaceuticals-inc-usa-voluntarily-recalls-all-unexpired-lots-its-ranitidine-tablets-and'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/glenmark-pharmaceuticals-inc-usa-voluntarily-recalls-all-unexpired-lots-its-ranitidine-tablets-and" class="external text external">"Glenmark Pharmaceuticals Inc., USA voluntarily recalls all unexpired lots of its Ranitidine tablets and ceases distribution, due to possible presence of N-nitrosodimethylamine (NDMA) impurity"</a>. <i>U.S. Food and Drug Administration</i>. 17 December 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191218221805/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/glenmark-pharmaceuticals-inc-usa-voluntarily-recalls-all-unexpired-lots-its-ranitidine-tablets-and  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191218221805/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/glenmark-pharmaceuticals-inc-usa-voluntarily-recalls-all-unexpired-lots-its-ranitidine-tablets-and'" tppabs="https://web.archive.org/web/20191218221805/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/glenmark-pharmaceuticals-inc-usa-voluntarily-recalls-all-unexpired-lots-its-ranitidine-tablets-and" class="external text external">Archived</a> from the original on 18 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">18 December</span> 2019</span>.</cite></span></li><li id="cite_note-100"> <span id="mw-reference-text-cite_note-100" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/appco-pharma-llc-issues-voluntary-nationwide-recall-ranitidine-hydrochloride-capsules-150-mg-and-300  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/appco-pharma-llc-issues-voluntary-nationwide-recall-ranitidine-hydrochloride-capsules-150-mg-and-300'" tppabs="http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/appco-pharma-llc-issues-voluntary-nationwide-recall-ranitidine-hydrochloride-capsules-150-mg-and-300" class="external text external">"Appco Pharma LLC issues voluntary nationwide recall of Ranitidine hydrochloride capsules 150 mg and 300 mg due to an elevated amount of unexpected impurity, N-nitrosodimethylamine (NDMA)"</a>. <i>U.S. Food and Drug Administration</i>. 7 January 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">8 January</span> 2020</span>.</cite></span></li><li id="cite_note-101"> <span id="mw-reference-text-cite_note-101" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/denton-pharma-inc-dba-northwind-pharmaceuticals-voluntarily-recalls-all-unexpired-lots-its  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/denton-pharma-inc-dba-northwind-pharmaceuticals-voluntarily-recalls-all-unexpired-lots-its'" tppabs="http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/denton-pharma-inc-dba-northwind-pharmaceuticals-voluntarily-recalls-all-unexpired-lots-its" class="external text external">"Denton Pharma, Inc. dba Northwind Pharmaceuticals voluntarily recalls all unexpired lots of its Ranitidine tablets and ceases distribution, due to possible presence of N-nitrosodimethylamine (NDMA) impurity"</a>. <i>U.S. Food and Drug Administration</i>. 6 January 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">8 January</span> 2020</span>.</cite></span></li><li id="cite_note-FDA_PR-102"> <span id="mw-reference-text-cite_note-FDA_PR-102" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/american-health-packaging-issues-voluntary-nationwide-recall-ranitidine-tablets-usp-150-mg-100-count  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/american-health-packaging-issues-voluntary-nationwide-recall-ranitidine-tablets-usp-150-mg-100-count'" tppabs="http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/american-health-packaging-issues-voluntary-nationwide-recall-ranitidine-tablets-usp-150-mg-100-count" class="external text external">"American Health Packaging issues voluntary nationwide recall of Ranitidine tablets, USP 150 mg, 100 count unit dose blisters due to the detection of N-nitrosodimethylamine (NDMA) impurity"</a>. <i>U.S. Food and Drug Administration</i>. 27 February 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">28 February</span> 2020</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-103"> <span id="mw-reference-text-cite_note-103" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/medical-product-safety-information/all-ranitidine-products-zantac-press-release-fda-requests-removal  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/medical-product-safety-information/all-ranitidine-products-zantac-press-release-fda-requests-removal'" tppabs="https://www.fda.gov/safety/medical-product-safety-information/all-ranitidine-products-zantac-press-release-fda-requests-removal" class="external text external">"All Ranitidine Products (Zantac): Press Release - FDA Requests Removal"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 1 April 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">6 May</span> 2020</span>.</cite></span></li><li id="cite_note-104"> <span id="mw-reference-text-cite_note-104" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020'" tppabs="https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-30-april-2020" class="external text external">"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020"</a>. <i>European Medicines Agency (EMA)</i>. 30 April 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">6 May</span> 2020</span>.</cite> Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</span></li><li id="cite_note-CHMP_withdrawl-105"> <span id="mw-reference-text-cite_note-CHMP_withdrawl-105" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/referrals/ranitidine-containing-medicinal-products  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/referrals/ranitidine-containing-medicinal-products'" tppabs="https://www.ema.europa.eu/en/medicines/human/referrals/ranitidine-containing-medicinal-products" class="external text external">"Ranitidine-containing medicinal products"</a>. <i>European Medicines Agency (EMA)</i>. 30 April 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">6 May</span> 2020</span>.</cite> Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</span></li><li id="cite_note-EMA_Nitrosamine_impurities-106"> <span id="mw-reference-text-cite_note-EMA_Nitrosamine_impurities-106" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/human-regulatory/post-authorisation/referral-procedures/nitrosamine-impurities  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/human-regulatory/post-authorisation/referral-procedures/nitrosamine-impurities'" tppabs="https://www.ema.europa.eu/en/human-regulatory/post-authorisation/referral-procedures/nitrosamine-impurities" class="external text external">"Nitrosamine impurities"</a>. <i>European Medicines Agency</i>. 23 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">6 August</span> 2020</span>.</cite> Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</span></li><li id="cite_note-107"> <span id="mw-reference-text-cite_note-107" class="mw-reference-text"><cite id="CITEREFLednicer1993" class="citation book cs1">Lednicer D, ed. (1993). <i>Chronicles of Drug Discovery</i>. ACS Professional Reference Book. <b>3</b>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>45–81. ISBN<span>&nbsp;</span><bdi>978-0-8412-2733-0</bdi>.</cite></span></li><li id="cite_note-108"> <span id="mw-reference-text-cite_note-108" class="mw-reference-text"><span class="citation patent"><a href="javascript:if(confirm('https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=US4128658  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=US4128658'" tppabs="https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=US4128658" class="external text external">US<span> </span>patent 4128658</a>,<span> </span>"Aminoalkyl furan derivatives"</span></span></li><li id="cite_note-109"> <span id="mw-reference-text-cite_note-109" class="mw-reference-text"><cite id="CITEREFLaurence_BruntonJohn_LazoKeith_Parker2005" class="citation book cs1">Laurence Brunton, John Lazo, Keith Parker (August 2005). <a href="javascript:if(confirm('https://web.archive.org/web/20160411074421/http://www.mhprofessional.com/product.php?isbn=0071422803  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160411074421/http://www.mhprofessional.com/product.php?isbn=0071422803'" tppabs="https://web.archive.org/web/20160411074421/http://www.mhprofessional.com/product.php?isbn=0071422803" class="external text external"><i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i></a> (11 ed.). McGraw-Hill. p.<span>&nbsp;</span>972. doi:<a href="javascript:if(confirm('https://doi.org/10.1036%2F0071422803  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1036%2F0071422803'" tppabs="https://doi.org/10.1036%2F0071422803" class="external text external">10.1036/0071422803</a>. ISBN<span>&nbsp;</span><bdi>978-0-07-142280-2</bdi>. Archived from <a href="javascript:if(confirm('http://mhprofessional.com/product.php?isbn=0071422803  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://mhprofessional.com/product.php?isbn=0071422803'" tppabs="http://mhprofessional.com/product.php?isbn=0071422803" class="external text external">the original</a> on 11 April 2016.</cite></span></li><li id="cite_note-110"> <span id="mw-reference-text-cite_note-110" class="mw-reference-text">Pelot, Daniel, (M.D.). "<i>Digestive System<span>&nbsp;</span>: New Drug for Heartburn</i>". The New Book of Knowledge<span>&nbsp;</span>: Medicine &amp; Health, Grolier<span>&nbsp;</span>: Danbury, Connecticut. 1990. p.262. ISBN<span>&nbsp;</span>0-7172-8244-9. Library of Congress 82-645223</span></li><li id="cite_note-111"> <span id="mw-reference-text-cite_note-111" class="mw-reference-text"><cite id="CITEREFYeomansTulassayJuhászRácz1998" class="citation journal cs1">Yeomans ND, Tulassay Z, Juhász L,  et al. (March 1998). "A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal anti-inflammatory drugs.  Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group". <i>N. Engl. J. Med</i>. <b>338</b> (11): 719–26. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJM199803123381104  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJM199803123381104'" tppabs="https://doi.org/10.1056%2FNEJM199803123381104" class="external text external">10.1056/NEJM199803123381104</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9494148  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9494148'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9494148" class="external text external">9494148</a>.</cite></span></li><li id="cite_note-112"> <span id="mw-reference-text-cite_note-112" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021698  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021698'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021698" class="external text external">"Zantac"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. NDA 021698<span class="reference-accessdate">. Retrieved <span class="nowrap">18 October</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-113"> <span id="mw-reference-text-cite_note-113" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.biopharmadive.com/news/cvs-zantac-voluntary-recall-ndma-carcinogen/563990/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.biopharmadive.com/news/cvs-zantac-voluntary-recall-ndma-carcinogen/563990/'" tppabs="https://www.biopharmadive.com/news/cvs-zantac-voluntary-recall-ndma-carcinogen/563990/" class="external text external">"CVS suspends Zantac sales, as recalls widen over carcinogen fears"</a>. <i>BioPharma Dive</i>. 30 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">18 October</span> 2019</span>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/rn/66357-35-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/rn/66357-35-5'" tppabs="https://druginfo.nlm.nih.gov/drugportal/rn/66357-35-5" class="external text external">"Ranitidine"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Drugs_for_peptic_ulcer_and_GERD/GORD_(A02B)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Drugs_for_peptic_ulcer_and_GERD/GORD_(A02B)" style="font-size:114%;margin:0 4em">Drugs for peptic ulcer and GERD/GORD (A02B)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">H<sub>2</sub> antagonists ("-tidine")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">Cimetidine</a></li>
<li><a href="Famotidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Famotidine" title="Famotidine">Famotidine</a></li>
<li>Lafutidine</li>
<li>Lavoltidine (loxtidine)</li>
<li>Niperotidine</li>
<li><a href="Nizatidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nizatidine" title="Nizatidine">Nizatidine</a></li>
<li><a href="Ranitidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ranitidine" title="Ranitidine">Ranitidine</a><sup>#</sup></li>
<li>Roxatidine</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Prostaglandins (E)/analogues ("-prost-")</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Misoprostol.htm" tppabs="https://ptable.com/wiki/compounds/A/Misoprostol" title="Misoprostol">Misoprostol</a></li>
<li>Enprostil</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Proton-pump inhibitors ("-prazole")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Azeloprazole</li>
<li>Dexlansoprazole</li>
<li><a href="Esomeprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Esomeprazole" title="Esomeprazole">Esomeprazole</a></li>
<li>Ilaprazole</li>
<li><a href="Lansoprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Lansoprazole" title="Lansoprazole">Lansoprazole</a></li>
<li><a href="Omeprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Omeprazole" title="Omeprazole">Omeprazole</a><sup>#</sup></li>
<li><a href="Pantoprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Pantoprazole" title="Pantoprazole">Pantoprazole</a></li>
<li><span class="new">Picoprazole</span></li>
<li><a href="Rabeprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Rabeprazole" title="Rabeprazole">Rabeprazole</a></li>
<li>Tenatoprazole</li>
<li>Timoprazole</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Potassium-competitive acid blockers ("-prazan")</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">Linaprazan</span></li>
<li>Revaprazan</li>
<li><span class="new">Soraprazan</span></li>
<li>Vonoprazan</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Aceglutamide aluminum</li>
<li>Acetoxolone</li>
<li>Alginic acid</li>
<li>Arbaclofen placarbil</li>
<li>Bismuth subcitrate</li>
<li><a href="Carbenoxolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbenoxolone" title="Carbenoxolone">Carbenoxolone</a></li>
<li><a href="Cetraxate.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetraxate" title="Cetraxate">Cetraxate</a></li>
<li>Gefarnate</li>
<li>Lesogaberan</li>
<li><a href="Pirenzepine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pirenzepine" title="Pirenzepine">Pirenzepine</a></li>
<li>Proglumide</li>
<li><a href="Rebamipide.htm" tppabs="https://ptable.com/wiki/compounds/A/Rebamipide" title="Rebamipide">Rebamipide</a></li>
<li><a href="Sucralfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Sucralfate" title="Sucralfate">Sucralfate</a></li>
<li>Sulglicotide</li>
<li><a href="Telenzepine.htm" tppabs="https://ptable.com/wiki/compounds/A/Telenzepine" title="Telenzepine">Telenzepine</a></li>
<li>Teprenone</li>
<li>Troxipide</li>
<li>Zinc L-carnosine</li>
<li>Zolimidine</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Combinations</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Bismuth subcitrate/metronidazole/tetracycline</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>See also: <i>Helicobacter pylori</i> eradication protocols</i></li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Histamine_receptor_modulators" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Histamine_receptor_modulators" style="font-size:114%;margin:0 4em">Histamine receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center;">H<sub>1</sub></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> 2-Pyridylethylamine</li>
<li><a href="Betahistine.htm" tppabs="https://ptable.com/wiki/compounds/A/Betahistine" title="Betahistine">Betahistine</a></li>
<li><a href="Histamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine" title="Histamine">Histamine</a></li>
<li>HTMT</li>
<li><span style="font-size:90%;">L</span>-Histidine</li>
<li>UR-AK49</li></ul>

<ul><li><b>Antagonists:</b> <i>First-generation:</i> 4-Methyldiphenhydramine</li>
<li><a href="Alimemazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Alimemazine" title="Alimemazine">Alimemazine</a></li>
<li><a href="Antazoline.htm" tppabs="https://ptable.com/wiki/compounds/A/Antazoline" title="Antazoline">Antazoline</a></li>
<li><a href="Azatadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Azatadine" title="Azatadine">Azatadine</a></li>
<li>Bamipine</li>
<li><a href="Benzatropine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzatropine" title="Benzatropine">Benzatropine (benztropine)</a></li>
<li><a href="Bepotastine.htm" tppabs="https://ptable.com/wiki/compounds/A/Bepotastine" title="Bepotastine">Bepotastine</a></li>
<li><a href="Bromazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Bromazine" title="Bromazine">Bromazine</a></li>
<li><a href="Brompheniramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Brompheniramine" title="Brompheniramine">Brompheniramine</a></li>
<li><a href="Buclizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Buclizine" title="Buclizine">Buclizine</a></li>
<li>Captodiame</li>
<li><a href="Carbinoxamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbinoxamine" title="Carbinoxamine">Carbinoxamine</a></li>
<li><a href="Chlorcyclizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorcyclizine" title="Chlorcyclizine">Chlorcyclizine</a></li>
<li>Chloropyramine</li>
<li><a href="Chlorothen.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorothen" title="Chlorothen">Chlorothen</a></li>
<li><a href="Chlorphenamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorphenamine" title="Chlorphenamine">Chlorphenamine</a></li>
<li>Chlorphenoxamine</li>
<li><a href="Cinnarizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cinnarizine" title="Cinnarizine">Cinnarizine</a></li>
<li><a href="Clemastine.htm" tppabs="https://ptable.com/wiki/compounds/A/Clemastine" title="Clemastine">Clemastine</a></li>
<li>Clobenzepam</li>
<li>Clocinizine</li>
<li>Cloperastine</li>
<li><a href="Cyclizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclizine" title="Cyclizine">Cyclizine</a></li>
<li><a href="Cyproheptadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyproheptadine" title="Cyproheptadine">Cyproheptadine</a></li>
<li>Dacemazine</li>
<li><span class="new">Decloxizine</span></li>
<li>Deptropine</li>
<li><a href="Dexbrompheniramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexbrompheniramine" title="Dexbrompheniramine">Dexbrompheniramine</a></li>
<li>Dexchlorpheniramine</li>
<li><a href="Dimenhydrinate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dimenhydrinate" title="Dimenhydrinate">Dimenhydrinate</a></li>
<li>Dimetindene</li>
<li><a href="Diphenhydramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Diphenhydramine" title="Diphenhydramine">Diphenhydramine</a></li>
<li>Diphenylpyraline</li>
<li><a href="Doxylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Doxylamine" title="Doxylamine">Doxylamine</a></li>
<li>Embramine</li>
<li>Etodroxizine</li>
<li>Etybenzatropine (ethylbenztropine)</li>
<li>Etymemazine</li>
<li>Fenethazine</li>
<li><a href="Flunarizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Flunarizine" title="Flunarizine">Flunarizine</a></li>
<li>Histapyrrodine</li>
<li>Homochlorcyclizine</li>
<li>Hydroxyethylpromethazine</li>
<li><a href="Hydroxyzine.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydroxyzine" title="Hydroxyzine">Hydroxyzine</a></li>
<li>Isopromethazine</li>
<li>Isothipendyl</li>
<li><a href="Meclozine.htm" tppabs="https://ptable.com/wiki/compounds/A/Meclozine" title="Meclozine" class="mw-redirect">Meclozine</a></li>
<li>Medrylamine</li>
<li><a href="Mepyramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mepyramine" title="Mepyramine">Mepyramine (pyrilamine)</a></li>
<li><a href="Mequitazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mequitazine" title="Mequitazine">Mequitazine</a></li>
<li>Methafurylene</li>
<li><a href="Methapyrilene.htm" tppabs="https://ptable.com/wiki/compounds/A/Methapyrilene" title="Methapyrilene">Methapyrilene</a></li>
<li><a href="Methdilazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Methdilazine" title="Methdilazine">Methdilazine</a></li>
<li>Moxastine</li>
<li><a href="Orphenadrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Orphenadrine" title="Orphenadrine">Orphenadrine</a></li>
<li><a href="Oxatomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxatomide" title="Oxatomide">Oxatomide</a></li>
<li>Oxomemazine</li>
<li>Perlapine</li>
<li><a href="Phenindamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenindamine" title="Phenindamine">Phenindamine</a></li>
<li><a href="Pheniramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pheniramine" title="Pheniramine">Pheniramine</a></li>
<li>Phenyltoloxamine</li>
<li>Pimethixene</li>
<li>Piperoxan</li>
<li>Pipoxizine</li>
<li><a href="Promethazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Promethazine" title="Promethazine">Promethazine</a></li>
<li><a href="Propiomazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Propiomazine" title="Propiomazine">Propiomazine</a></li>
<li>Pyrrobutamine</li>
<li>Talastine</li>
<li><a href="Thenalidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Thenalidine" title="Thenalidine">Thenalidine</a></li>
<li><a href="Thenyldiamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Thenyldiamine" title="Thenyldiamine">Thenyldiamine</a></li>
<li><a href="Thiazinamium_metilsulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiazinamium" title="Thiazinamium" class="mw-redirect">Thiazinamium</a></li>
<li><a href="Thonzylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Thonzylamine" title="Thonzylamine">Thonzylamine</a></li>
<li>Tolpropamine</li>
<li><a href="Tripelennamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tripelennamine" title="Tripelennamine">Tripelennamine</a></li>
<li><a href="Triprolidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Triprolidine" title="Triprolidine">Triprolidine</a></li></ul>

<ul><li><i>Second/third-generation:</i> <a href="Acrivastine.htm" tppabs="https://ptable.com/wiki/compounds/A/Acrivastine" title="Acrivastine">Acrivastine</a></li>
<li><span class="new">Alinastine</span></li>
<li><a href="Astemizole.htm" tppabs="https://ptable.com/wiki/compounds/A/Astemizole" title="Astemizole">Astemizole</a></li>
<li><a href="Azelastine.htm" tppabs="https://ptable.com/wiki/compounds/A/Azelastine" title="Azelastine">Azelastine</a></li>
<li><span class="new">Bamirastine</span></li>
<li><span class="new">Barmastine</span></li>
<li><span class="new">Bepiastine</span></li>
<li><a href="Bepotastine.htm" tppabs="https://ptable.com/wiki/compounds/A/Bepotastine" title="Bepotastine">Bepotastine</a></li>
<li>Bilastine</li>
<li><span class="new">Cabastinen</span></li>
<li><span class="new">Carebastine</span></li>
<li><a href="Cetirizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetirizine" title="Cetirizine">Cetirizine</a></li>
<li><a href="Clemastine.htm" tppabs="https://ptable.com/wiki/compounds/A/Clemastine" title="Clemastine">Clemastine</a></li>
<li>Clemizole</li>
<li>Clobenztropine</li>
<li><a href="Desloratadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Desloratadine" title="Desloratadine">Desloratadine</a></li>
<li><span class="new">Dorastine</span></li>
<li>Ebastine</li>
<li><span class="new">Efletirizine</span></li>
<li><a href="Emedastine.htm" tppabs="https://ptable.com/wiki/compounds/A/Emedastine" title="Emedastine">Emedastine</a></li>
<li><a href="Epinastine.htm" tppabs="https://ptable.com/wiki/compounds/A/Epinastine" title="Epinastine">Epinastine</a></li>
<li><a href="Fexofenadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Fexofenadine" title="Fexofenadine">Fexofenadine</a></li>
<li><span class="new">Flezelastine</span></li>
<li><a href="Ketotifen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketotifen" title="Ketotifen">Ketotifen</a></li>
<li>Latrepirdine</li>
<li><a href="Levocabastine.htm" tppabs="https://ptable.com/wiki/compounds/A/Levocabastine" title="Levocabastine">Levocabastine</a></li>
<li>Levocetirizine</li>
<li><span class="new">Linetastine</span></li>
<li><a href="Loratadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Loratadine" title="Loratadine">Loratadine</a></li>
<li><span class="new">Mapinastine</span></li>
<li>Mebhydrolin</li>
<li>Mizolastine</li>
<li>Moxastine</li>
<li><span class="new">Noberastine</span></li>
<li><span class="new">Octastine</span></li>
<li><a href="Olopatadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Olopatadine" title="Olopatadine">Olopatadine</a></li>
<li><span class="new">Perastine</span></li>
<li><span class="new">Pibaxizine</span></li>
<li><span class="new">Piclopastine</span></li>
<li>Quifenadine (phencarol)</li>
<li><span class="new">Rocastine</span></li>
<li>Rupatadine</li>
<li>Setastine</li>
<li><span class="new">Sequifenadine (bicarphen)</span></li>
<li>Talastine</li>
<li><span class="new">Temelastine</span></li>
<li><a href="Terfenadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Terfenadine" title="Terfenadine">Terfenadine</a></li>
<li><span class="new">Vapitadine</span></li>
<li><span class="new">Zepastine</span></li></ul>

<ul><li><i>Others:</i> Atypical antipsychotics (e.g., <a href="Aripiprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Aripiprazole" title="Aripiprazole">aripiprazole</a>, asenapine, brexpiprazole, brilaroxazine, <a href="Clozapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Clozapine" title="Clozapine">clozapine</a>, iloperidone, <a href="Olanzapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Olanzapine" title="Olanzapine">olanzapine</a>, <a href="Paliperidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Paliperidone" title="Paliperidone">paliperidone</a>, <a href="Quetiapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Quetiapine" title="Quetiapine">quetiapine</a>, <a href="Risperidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Risperidone" title="Risperidone">risperidone</a>, <a href="Ziprasidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ziprasidone" title="Ziprasidone">ziprasidone</a>, zotepine)</li>
<li><a href="Phenylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylpiperazine" title="Phenylpiperazine">Phenylpiperazine</a> antidepressants (e.g., hydroxynefazodone, <a href="Nefazodone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nefazodone" title="Nefazodone">nefazodone</a>, <a href="Trazodone.htm" tppabs="https://ptable.com/wiki/compounds/A/Trazodone" title="Trazodone">trazodone</a>, triazoledione)</li>
<li>Tetracyclic antidepressants (e.g., <a href="Amoxapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amoxapine" title="Amoxapine">amoxapine</a>, <a href="Loxapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Loxapine" title="Loxapine">loxapine</a>, <a href="Maprotiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Maprotiline" title="Maprotiline">maprotiline</a>, <a href="Mianserin.htm" tppabs="https://ptable.com/wiki/compounds/A/Mianserin" title="Mianserin">mianserin</a>, <a href="Mirtazapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mirtazapine" title="Mirtazapine">mirtazapine</a>, oxaprotiline)</li>
<li>Tricyclic antidepressants (e.g., <a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">amitriptyline</a>, butriptyline, <a href="Clomipramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Clomipramine" title="Clomipramine">clomipramine</a>, desipramine, dosulepin (dothiepin), <a href="Doxepin.htm" tppabs="https://ptable.com/wiki/compounds/A/Doxepin" title="Doxepin">doxepin</a>, <a href="Imipramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Imipramine" title="Imipramine">imipramine</a>, iprindole, lofepramine, <a href="Nortriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Nortriptyline" title="Nortriptyline">nortriptyline</a>, <a href="Protriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Protriptyline" title="Protriptyline">protriptyline</a>, <a href="Trimipramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Trimipramine" title="Trimipramine">trimipramine</a>)</li>
<li>Typical antipsychotics (e.g., <a href="Chlorpromazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorpromazine" title="Chlorpromazine">chlorpromazine</a>, <a href="Flupentixol.htm" tppabs="https://ptable.com/wiki/compounds/A/Flupenthixol" title="Flupenthixol" class="mw-redirect">flupenthixol</a>, <a href="Fluphenazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluphenazine" title="Fluphenazine">fluphenazine</a>, <a href="Loxapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Loxapine" title="Loxapine">loxapine</a>, <a href="Perphenazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Perphenazine" title="Perphenazine">perphenazine</a>, <a href="Prochlorperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Prochlorperazine" title="Prochlorperazine">prochlorperazine</a>, <a href="Thioridazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Thioridazine" title="Thioridazine">thioridazine</a>, <a href="Thiothixene.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiothixene" title="Thiothixene" class="mw-redirect">thiothixene</a>)</li></ul>

<ul><li><i>Unknown/unsorted:</i> <span class="new">Azanator</span></li>
<li><span class="new">Belarizine</span></li>
<li><span class="new">Elbanizine</span></li>
<li><span class="new">Flotrenizine</span></li>
<li><span class="new">GSK1004723</span></li>
<li><span class="new">Napactadine</span></li>
<li><span class="new">Tagorizine</span></li>
<li><span class="new">Trelnarizine</span></li>
<li><span class="new">Trenizine</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center;">H<sub>2</sub></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> Amthamine</li>
<li><a href="Betazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Betazole" title="Betazole">Betazole</a></li>
<li>Dimaprit</li>
<li><a href="Histamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine" title="Histamine">Histamine</a></li>
<li>HTMT</li>
<li>Impromidine</li>
<li><span style="font-size:90%;">L</span>-Histidine</li>
<li>UR-AK49</li></ul>

<ul><li><b>Antagonists:</b> <span class="new">Bisfentidine</span></li>
<li>Burimamide</li>
<li><a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">Cimetidine</a></li>
<li><span class="new">Dalcotidine</span></li>
<li><span class="new">Donetidine</span></li>
<li>Ebrotidine</li>
<li><span class="new">Etintidine</span></li>
<li><a href="Famotidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Famotidine" title="Famotidine">Famotidine</a></li>
<li><span class="new">Isolamtidine</span></li>
<li>Lafutidine</li>
<li><span class="new">Lamtidine</span></li>
<li>Lavoltidine (loxtidine)</li>
<li>Lupitidine</li>
<li>Metiamide</li>
<li><span class="new">Mifentidine</span></li>
<li>Niperotidine</li>
<li><a href="Nizatidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nizatidine" title="Nizatidine">Nizatidine</a></li>
<li><span class="new">Osutidine</span></li>
<li>Oxmetidine</li>
<li><span class="new">Pibutidine</span></li>
<li><span class="new">Quisultazine (quisultidine)</span></li>
<li><span class="new">Ramixotidine</span></li>
<li><a href="Ranitidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ranitidine" title="Ranitidine">Ranitidine</a></li>
<li>Roxatidine</li>
<li>Sufotidine</li>
<li><span class="new">Tiotidine</span></li>
<li><span class="new">Tuvatidine</span></li>
<li><span class="new">Venritidine</span></li>
<li><span class="new">Xaltidine</span></li>
<li>Zolantidine</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center;">H<sub>3</sub></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> α-Methylhistamine</li>
<li>Cipralisant</li>
<li><a href="Histamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine" title="Histamine">Histamine</a></li>
<li>Imetit</li>
<li>Immepip</li>
<li>Immethridine</li>
<li><span style="font-size:90%;">L</span>-Histidine</li>
<li>Methimepip</li>
<li>Proxyfan</li></ul>

<ul><li><b>Antagonists:</b> A-349821</li>
<li>A-423579</li>
<li>ABT-239</li>
<li><span class="new">ABT-652</span></li>
<li><span class="new">AZD5213</span></li>
<li><span class="new">Bavisant</span></li>
<li><a href="Betahistine.htm" tppabs="https://ptable.com/wiki/compounds/A/Betahistine" title="Betahistine">Betahistine</a></li>
<li>Burimamide</li>
<li>Ciproxifan</li>
<li>Clobenpropit</li>
<li>Conessine</li>
<li><span class="new">Enerisant</span></li>
<li>GSK-189254</li>
<li>Impentamine</li>
<li>Iodophenpropit</li>
<li><span class="new">Irdabisant</span></li>
<li>JNJ-5207852</li>
<li>NNC 38-1049</li>
<li>PF-03654746</li>
<li>Pitolisant</li>
<li>SCH-79687</li>
<li>Thioperamide</li>
<li>VUF-5681</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center;">H<sub>4</sub></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><b>Agonists:</b> 4-Methylhistamine</li>
<li>α-Methylhistamine</li>
<li><a href="Histamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine" title="Histamine">Histamine</a></li>
<li><span style="font-size:90%;">L</span>-Histidine</li>
<li>OUP-16</li>
<li>VUF-8430</li></ul>

<ul><li><b>Antagonists:</b> JNJ-7777120</li>
<li><a href="Mianserin.htm" tppabs="https://ptable.com/wiki/compounds/A/Mianserin" title="Mianserin">Mianserin</a></li>
<li><span class="new">Seliforant</span></li>
<li>Thioperamide</li>
<li><span class="new">Toreforant</span></li>
<li>VUF-6002</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div><i><b>See also:</b> Receptor/signaling modulators • Monoamine metabolism modulators • Monoamine reuptake inhibitors</i></div></td></tr></tbody></table></div><span>
</span>
<div role="navigation" class="navbox" aria-labelledby="GlaxoSmithKline" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="GlaxoSmithKline" style="font-size:114%;margin:0 4em">GlaxoSmithKline</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Subsidiaries</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>GlaxoSmithKline Pakistan</li>
<li>GlaxoSmithKline Pharmaceuticals Ltd</li>
<li>Stiefel Laboratories</li>
<li>Tesaro</li>
<li>ViiV Healthcare (85%)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Predecessors,<br>acquisitions</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Allen &amp; Hanburys</li>
<li>Beecham Group</li>
<li>Block Drug</li>
<li>Burroughs Wellcome</li>
<li>Glaxo</li>
<li>Glaxo Wellcome</li>
<li>Human Genome Sciences</li>
<li>Recherche et Industrie Thérapeutiques</li>
<li>Reliant Pharmaceuticals</li>
<li>S. E. Massengill Company</li>
<li>SmithKline Beecham</li>
<li>Smith, Kline &amp; French</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Products</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Current</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Pharma</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Advair</li>
<li><a href="Orlistat.htm" tppabs="https://ptable.com/wiki/compounds/A/Orlistat" title="Orlistat">Alli</a></li>
<li>Augmentin</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Rosiglitazone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Rosiglitazone'" tppabs="https://ptable.com/wiki/compounds/A/Rosiglitazone" title="Rosiglitazone">Avandia</a></li>
<li>Beconase</li>
<li><a href="Ibandronic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibandronic_acid" title="Ibandronic acid">Boniva</a></li>
<li><a href="Fluticasone_propionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluticasone_propionate" title="Fluticasone propionate">Flixonase</a></li>
<li>Hycamtin</li>
<li><a href="Lamotrigine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lamotrigine" title="Lamotrigine">Lamictal</a></li>
<li><a href="Paroxetine.htm" tppabs="https://ptable.com/wiki/compounds/A/Paroxetine" title="Paroxetine">Paxil/Seroxat</a></li>
<li>Serlipet</li>
<li><a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">Tagamet</a></li>
<li><a href="Salbutamol.htm" tppabs="https://ptable.com/wiki/compounds/A/Salbutamol" title="Salbutamol">Ventolin</a></li>
<li><a href="Bupropion.htm" tppabs="https://ptable.com/wiki/compounds/A/Bupropion" title="Bupropion">Wellbutrin/Zyban</a></li>
<li><a href="Ranitidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ranitidine" title="Ranitidine">Zantac</a> … <b>more</b></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Vaccines</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Hepatyrix</li>
<li>Pandemrix</li>
<li>Twinrix</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Aquafresh</li>
<li>Horlicks</li>
<li>Nicoderm</li>
<li>Nicorette</li>
<li>NiQuitin</li>
<li>Sensodyne</li>
<li>Tums … <b>more</b></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Former</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>BC Powder</li>
<li>Geritol</li>
<li>Goody's Powder</li>
<li>Lucozade</li>
<li>Ribena</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">People</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Board of <br>Directors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Philip Hampton</li>
<li>Emma Walmsley</li>
<li>Simon Dingemans</li>
<li>Roy M. Anderson</li>
<li>Manvinder Banga </li>
<li>Patrick Vallance</li>
<li>Vivienne Cox</li>
<li>Lynn Elsenhans</li>
<li>Jesse Goodman</li>
<li>Judy Lewent</li>
<li>Urs Rohner</li>
<li>Laurie Glimcher</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Thomas Beecham</li>
<li>Silas M. Burroughs</li>
<li>Mahlon Kline</li>
<li>John K. Smith</li>
<li>Henry Wellcome</li>
<li>Andrew Witty</li>
<li>Chris Gent</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Litigation</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Canada v. GlaxoSmithKline Inc.</i></li>
<li><i>Christopher v. SmithKline Beecham Corp.</i></li>
<li><i>GlaxoSmithKline Services Unlimited v Commission</i></li>
<li><i>United States v. Glaxo Group Ltd.</i></li>
<li><i>United States v. GlaxoSmithKline</i></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Drug Industry Documents Archive</li>
<li>GlaxoSmithKline Prize</li>
<li><i>Side Effects</i></li>
<li>Study 329</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<ul><li><figure-inline><span><img src="../I/m/Folder_Hexagonal_Icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Folder_Hexagonal_Icon.svg.png" data-file-width="36" data-file-height="31" data-file-type="drawing" height="14" width="16"></span></figure-inline> <b>Category</b></li></ul>
</div></td></tr></tbody></table></div>














<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>